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INTRODUCTION 
Novel Drug Delivery System: 
Novel Drug Delivery system (NDDS) refers to the approaches, formulations, 
technologies, and systems for transporting a pharmaceutical compound in the body as 
needed to safely achieve its desired therapeutic effects. NDDS is a system for delivery 
of drug other than conventional drug delivery system. NDDS is a combination of 
advance technique and dosage form which are far better than conventional dosage 
form1.The aim of NDDS is to provide a therapeutic amount of drug to the appropriate 
site in the body to accomplish promptly and then maintain the desired drug 
concentration2. NDDS combining polymer science, pharmaceutics and molecular 
biology3.   
ADVANTAGES OF NOVEL DRUG DELIVERY SYSTEM4,5: 
i. Optimum dose at the right time and right location  
ii. Efficient use of expensive drugs, excipients and reduction in production cost  
iii. Improves the therapy by increasing the duration of action and reducing the side 
effects. 
iv. Increases the patient compliance and provides convenient route of 
administration. 
v. Achieve the targeting of drugs to a specific sites which reduces the unwanted 
side effects and obtain maximum efficacy. 
vi. Reduces the dose and thus reduces the side effects of drugs. 
Types of novel drug delivery systems4,5: 
There are number of novel drug delivery systems are available. They are 
1. Hydrogels 
2. Colloidal drug carrier systems 
a) Micelles 
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b) Microspheres 
c) Nanoparticles 
d) Liposomes and neosomes 
3. Mucoadhesives 
4. Transdermal drug delivery 
5. Ocular drug delivery 
6. Nasal drug delivery 
1. Hydrogels: 
Hydrogels are three dimensional hydrophilic polymeric networks capable of 
absorbing large amount of water or biological fluids. These networks are composed of 
homopolymers or copolymers and are insoluble because of the presence of chemical or 
physical crosslinks like entanglements or crystallites. The hydrogels exhibit 
thermodynamic compatibility with water which allows them to swell in aqueous 
medium. They are used to control the drug release in reservoir based controlled release 
system or as carriers in swellable and swelling control release devices4. 
 
2. Colloidal Drug Carrier Systems: 
Colloidal drug carrier systems like micellar solutions, vesicle and liquid crystal 
dispersions, microspheres, nanoparticles, consisting of small particles, ranging from 10 
nm to 400 nm diameter. They show great promise as drug delivery systems. When 
developing these formulations the aim is to obtain systems with optimized drug loading 
and release properties, long shelf life and low toxicity4. 
 
a) Micelles: 
Micelles formed by the self-assemble of amphiphilc block copolymers in 
aqueous solutions. The size ranges from 5 to 50 nm. They will provide grate interest in 
drug delivery applications. The drugs can be physically entrapped in the core of block 
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co polymer micelle and transported at concentration that can exceed their intrinsic water 
solubility4. 
 
b) Microspheres: 
Microspheres are the delivery systems that contain a matrix of the polymer in 
which the drug in micron size is uniformly dispersed5. It comprises of small spherical 
particles, with diameters in the micrometer range, typically 1µm to 1000µm5. 
Microcapsules are those where the drug is coated with the polymer4. The microcapsules 
and microspheres prolong drug release whereas microspheres are used for drug 
targeting4. 
 
c) Nanoparticles: 
The size ranges from 10 to 1000 nm. They can absorb and encapsulate a drug 
thus protecting it from chemical and enzymatic degradation. The nanocapsules are 
vesicular systems in which the drug is confined to a cavity surrounded by a unique 
polymer membrane. Nanospheres are matrix systems in which the drug is physically 
and uniformly dispersed. Nanoparticles as drug carriers will be formed from both 
biodegradable and non-biodegradable polymers. They will provide massive advantages 
regarding drug targeting, delivery, and release4. Especially, used for the delivery of 
lipophilic compounds5. 
 
d) Liposomes and Niosomes: 
Liposomes are concentric bi-layered vesicles in which aqueous volume is 
entirely enclosed by a membranous lipid bi-layer mainly composed of natural or 
synthetic phospholipids. The liposomes are spherical particles that encapsulate the 
solvents which are freely floating in the interior5. Amphiphillic and lipophilic 
molecules are solubilised with in the phospholipid bi layer according to their affinity 
towards phospholipids. Presence of non-ionic surfactant instead of phospholipids in the 
formation of bilayers results in the formation of neosomes4.  
 
3. Mucoadhesive Systems: 
Mucoadhesives are synthetic or natural polymers that interact with the mucus 
layer covering the mucosal epithelial surface and mucin molecules. They can adhere to 
the gastric mucosa or the buccal mucosa. This concept has altered the possibility that 
these polymers can be used to overcome physiological barriers in long term drug 
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delivery. This mucoadhesive drug delivery system gives more effective and safe 
treatment not only for topical disorders but also for systemic problems4. 
4. Transdermal Drug Delivery: 
   Transdermal drug delivery is defined as self-contained, discrete dosage 
forms which, when applied to the intact skin, deliver the drug, through the skin at 
controlled rate to the systemic circulation6.  If the skin is the site of action then high 
concentration of drugs can be localized at the skin, which results in reducing the 
systemic drug levels and also reducing the systemic side effects. It is an alternative 
route for the delivery of systemically acting drugs. This route have several advantages 
when compared with oral drug administration. It bypasses the lever there by the dose is 
reduced and the side effects are minimized4. 
 
5. Ocular Drug Delivery: 
Ocular drug delivery is the one of the most challenging drug delivery system. 
This field has improved significantly over the past 20 years. The improvements have 
largely focused on maintaining the drug in eyes for an extended period of time unlike 
conventional eye drops4. 
 
6. Nasal Drug Delivery: 
The nasal route appears to be an alternative to parenterals for administrating 
drugs intended for systemic effects. The nasal route provides rich vascularity high 
permeable structure for absorption. It avoids hepatic first pass metabolism. Proteins 
such as insulin are reported to have fast and sustained action when administered through 
the nasal route4. 
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LIPOSOMES-An Introduction 
Liposomes are colloidal, vesicular structure composed of one or more bilayers 
surrounding an equal number of aqueous compartment7. Liposomes are small artificial 
vesicles of spherical shape that can be created from cholesterol and natural nontoxic 
phospholipids. Due to their size and hydrophobic and hydrophilic character (besides 
biocompatibility), liposomes are promising systems for drug delivery8. The sphere like 
shell encapsulated a liquid interior which contain substances such as peptides, protein, 
hormones, enzymes, antibiotics, anti-fungal and anti-cancer agents7.  
Liposome properties differ considerably with lipid composition, surface 
charge, size, and the method of preparation. Furthermore, the choice of bilayer 
components determines the ‘rigidity’ or ‘fluidity’ and the charge of the bilayer. For 
instance, unsaturated phosphatidylcholine species from natural sources (egg or soybean 
phosphatidylcholine) give much more permeable and less stable bilayers, whereas the 
saturated phospholipids with long acyl chains (for example, 
dipalmitoylphosphatidylcholine) form a rigid, rather impermeable bilayer structure8.  
It has been displayed that phospholipids impulsively form closed structures 
when they are hydrated in aqueous solutions. Such vesicles which have one or more 
phospholipid bilayer membranes can transport aqueous or lipid drugs, depending on the 
nature of those drugs. Because lipids are amphipathic (both hydrophobic and 
hydrophilic) in aqueous media, their thermodynamic phase properties and self-
assembling characteristics influence entropically focused confiscation of their 
hydrophobic sections into spherical bilayers. Those layers are referred to as lamellae9.  
Liposomes particle sizes ranges from 30 nm to several micrometers. They 
consist of one or more lipid bilayers surrounding aqueous units, where the polar head 
groups are oriented in the pathway of the interior and exterior aqueous phases. On the 
other hand, self-aggregation of polar lipids is not limited to conventional bilayer 
structures which rely on molecular shape, temperature, and environmental and 
preparation conditions but may self-assemble into various types of colloidal particles10.  
 
Advantages of Liposomes: 
Some of the advantages of liposome are as follows1,8,11, 12: 
1) It can carry both water and lipid soluble drugs. 
2) Provides selective passive targeting to tumor tissues (liposomal doxorubicin). 
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3) Liposomes increased efficacy and therapeutic index of drug (actinomycin-D). 
4) Liposome increased stability via encapsulation. 
5) Liposomes are non-toxic, flexible, biocompatible, completely biodegradable, and 
non-immunogenic for systemic and non-systemic administrations. 
6) Liposomes reduce the toxicity of the encapsulated agent (amphotericin B, Taxol). 
7) Liposomes help reduce the exposure of sensitive tissues to toxic drugs. 
8) Site avoidance effect. 
9) Flexibility to couple with site-specific ligands to achieve active targeting. 
10) Improved pharmacokinetic effects (reduced elimination, increased circulation life 
times). 
11) It provide sustained release. 
12) It can be administered through various routes. 
13) It engenders incorporate micro and macro molecules. 
14) It also act as reservoir of drugs. 
15) Liposomes can modulate the distribution of drug. 
16) It direct interaction of the drug with cell. 
 
Disadvantages of Liposomes: 
Some of the disadvantages of liposome are as follows8,11: 
1) Low solubility. 
2) Sometimes phospholipid undergoes oxidation and hydrolysis-like reaction. 
3) Short half-life. 
4) Leakage and fusion of encapsulated drug/molecules. 
5) Production cost is high. 
6) Fewer stables. 
7) Quick uptake by cells of reticuloendothelial system (R.E.S). 
8)  Allergic reactions may occur to liposomal constituents. 
9)  Problem to targeting to various tissues due to their large size. 
 
Application of Liposomes: 
Liposomes for Brain Targeting: 
The biocompatible and biodegradable behavior of liposomes have recently led 
to their exploration as drug delivery system to brain. Liposomes with a small diameter 
(100 nm) as well as large diameter undergo free diffusion through the Blood Brain 
                                                                                                                    INTRODUCTION 
S.B.C.P          Page No. 7 
Barrier (BBB). However it is possible that a small unilamellar vesicles (SUVS) coupled 
to brain drug transport vectors may be transported through the BBB by receptor 
mediated or absorptive mediated transcytosis13. 
 
Liposome in Eye Disorders: 
   Liposome has been widely used to treat disorder of both anterior and 
posterior segment. The disease of eye includes dry eyes, keratitis, corneal transplant 
rejection, uveitis, endopthelmitis and proliferative vitro retinopathy. Retinal diseases 
are leading cause of blindness in advanced countries. Liposome is used as vector for 
genetic transfection and monoclonal antibody directed vehicle. The recent techniques 
of the treatment like applying of focal laser to heat induced release of liposomal drugs 
and dyes are used in the treatment of selective tumor and neo-vascular vessels 
occlusion, angiography, retinal and choroidal blood vessel stasis13. 
 
Liposome for Respiratory Drug Delivery System: 
Liposome is widely used in several types of respiratory disorders. The recent 
use of liposome for the delivery of DNA to the lung means that a greater understanding 
of their use in macromolecular delivery via inhalational is now emerging. Much of this 
new knowledge, including new lipids and analytical techniques, can be used in the 
development of liposome based protein formulations. For inhalation of liposome the 
liquid or dry form is taken and the drug release occurs during nebulization. Drug 
powder liposome has been produced by milling or by spray drying13. 
 
Liposomes in parasitic diseases and infections: 
Since conventional liposomes are digested by phagocytic cells in the body after 
intravenous administration, they are ideal vehicles for the targeting of drug molecules 
into these macrophages. The best known examples of this ‘Trojan horse-like’ 
mechanism are several parasitic diseases which normally reside in the cell of 
mononuclear phagocytic system. They include leishmaniasis and several fungal 
infections14. 
 
Macrophage activation and vaccination: 
Some natural toxins induce strong macrophage response which results in 
macrophage activation. This can be duplicated and improved by the use of liposomes 
because small molecules with immunogenic properties (haptens) cannot induce 
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immune response without being attached to a larger particle. For instance, liposomes 
containing muramyl tripeptide, the smallest bacterial cell wall subunit with 
immunogenic properties cause macrophage activation. Activated macrophages are 
larger and contain more granulomae and lysosome material. Their state lasts for a few 
days during which they show enhanced tumouricidal, virocidal and microbicidal 
activity14. 
 
Liposomes in anticancer therapy: 
Many different liposome formulations of various anticancer agents were shown 
to be less toxic than the free drug. Anthracyclines are drugs which stop the growth of 
dividing cells by intercalating into the DNA and therefore kill predominantly quickly 
dividing cells. These cells are in tumours, but also in gastrointestinal mucosa, hair and 
blood cells and therefore this class of drugs is very toxic14. 
 
Liposomes in bioengineering: 
Nucleic acids used in gene transfer are large, with molecular weights up to 
several million Daltons, highly charged and hydrophilic and therefore not easy to 
transfer across cell membranes. Additionally to classical methods, such as direct 
injection, phosphate precipitation and others, liposomes were tried as transfection 
vectors. They can deliver the encapsulated or bound nucleic acid into cells 
predominantly in two ways: the classical approach is to encapsulate the genetic material 
into liposomes and liposomes act as an endocytosis enhancer while recently the 
phosphate or DEAE precipitation was simulated by liposomes. In these cases the 
nucleic acid forms a complex with several cationic liposomes and the size of the 
complex and its adsorption on the cell surface catalyses endocytosis or, possibly, 
fusion14. 
 
Liposomes in cosmetics: 
Liposomes as a carrier itself offers advantages because lipids are well hydrated 
and can reduce the dryness of the skin which is a primary cause for its ageing. Also, 
liposomes can act to replenish lipids and, importantly, linolenic acid14. 
 
Liposomes in agro-food industry: 
Lipid molecules from fats to polar lipids, are one of the fundamental 
ingredients in almost any food. The sustained release system concept can be used in 
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various fermentation processes in which the encapsulated enzymes can greatly shorten 
fermentation times and improve the quality of the product. This is due to improved 
spatial and temporal release of the ingredient(s) as well as to their protection in 
particular phases of the process against chemical degradation. A classical example is 
cheese making14. 
 
Mechanism of Liposome Formation15: 
In aqueous medium, the lipid molecules in self-assembled structures are 
oriented in such a way that the polar portion of the molecule remains in contact with 
the polar environment and at the same time shields the non-polar part. Among the 
amphiphiles used in the drug delivery, viz. soap, detergents, polar lipids, the latter 
(polar lipids) are often employed to form concentric bilayered structures. However, in 
aqueous mixtures these molecules are able to form various phases, some of them are 
stable and others remain in the metastable state. At high concentrations of these polar 
lipids, liquid-crystalline phases are formed that upon dilution with an excess o water 
can be dispersed into relatively stable colloidal particles. 
 
 
 
Figure 1: Mechanism of liposome formation 
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Classification of liposomes: 
Liposome classification based on structural features  
Multilamellar Large Vesicles (MLV): 
In MLV, vesicles have an onion structure. Classically, several unilamellar 
vesicles will form on the inside of the other with smaller size, making a multilamellar 
structure of concentric phospholipid spheres separated by layers of water8. 
 
Unilamellar vesicles (UV): 
In UV liposomes, the vesicle has a single phospholipid bilayer sphere 
enclosing the aqueous solution. UV vesicles can be prepared in a variety sizes16: 
Small unilamellar vesicles (SUV) - 20 to 40 nm. 
Medium sized unilamellar vesicles (MUV) – 40 to 80 nm. 
Large unilamellar vesicles (LUV) – 10 to 1000 nm. 
Giant unilamellar vesicles (GUV) - > 1000 nm. 
 
Oligolamellar vesicles (OLV): 
OLV have large central aqueous cores surrounded by 2 to 10 bilayers16. 
 
Multivesicular vesicles (MVV):  
MVV first described as large clusters of smaller compartments sharing 
common bilayers, have been redefined to cover all structures of non-concentric vesicles 
inside a larger vesicle of 200 nm to 3µm17. 
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Figure 2: Classification of liposome formation 
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Methods of Liposomes Preparation: 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure No. 3 Methods of liposome preparation 
 
A. Passive loading techniques: 
In these passive loading technique the drug is encapsulated by incorporating an 
aqueous phase of a water-soluble (hydrophillic) drug or an organic phase of a lipid-
soluble drug initially or at predetermined stage during the preparation of the liposomes. 
The huge drug encapsulation efficiency can be achieved with the help of these passive 
Methods for liposomes preparaion 
Passive loading techniques Active loading techniques 
Mechanical dispersion method Solvent dispersion method Detergent removal method 
1) Ether injection method 
2) Ethanol injection method 
3) Double emulsion 
4) Reverse phase 
evaporation vesicles 
5) Stable pluri lamellar 
vesicles 
1) Detergent (cholate, 
alkylglycoside,triton x-
100) removal from 
mixed vesicles by 
 Dialysis 
 Column 
chromatography 
 dilution 
 Reconstitute sendai 
virus enveloped 
1. Lipid film hydration method 
2. Micro emulsification method 
3. Sonication 
4. French pressure cell 
5. Membrane extrusion 
6. Dried reconstituted vesicles 
7. Freeze thawed liposomes 
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loading technique which is more suitable for lipid-soluble drugs with a high 
resemblance to the lipid membrane.  
Different methods discuss under this class start with a lipid solution in organic 
solvent and nd up with lipid dispersion in water. The a choice of component are 
typically combined by co-dissolving the lipids in an organic solvent and the organic 
solvent is then seperated by film deposition under vacuum .When residual solvent is 
removed, the solid lipid mixture is hydrated with the help of aqueous buffer.  
The lipids spontaneously swell and hydrate to form liposome. Liposomal 
encapsulation technology (LET) is the latest delivery method used by medical 
researcher to transmit drugs that act as healing promoters to the definite body organs. 
LET is state of art method of preparing sub-microscopic bubbles called liposome18. 
 
1. Mechanical Dispersion Method: 
In these method variety component are mainly combined by co-dissolving the 
lipids in an organic solvent and after that the organic solvent is then separated by film 
deposition under vaccum. When all the solvent is evaporated, the solid lipid mixture is 
hydrated using aqueous phase. The lipids spontaneously swell and hydrate to form 
liposomes18. 
 
The following are types of mechanical dispersion methods: 
i. Lipid film hydration method: 
   The lipid-film hydration procedure is the most common and simple 
method for preparation of MLV by dissolving the phospholipids in the organic solvents: 
dichloromethane, chloroform, ethanol and chloroform-methanol mixture (2:1 v/v; 9:1 
v/v; 3:1 v/v). A thin and homogeneous lipid film is formed when solvent is evaporated 
under vacuum at the temperature: 45-60 ºC. Nitrogen gas is involved in order to 
completely remove the residual solvent. A solution of distilled water, phosphate buffer, 
phosphate saline buffer at pH 7.4 and normal saline buffer are used in hydration step. 
The time for the hydration process varied from 1 h to 2 h at the temperature 60- 70 ºC. 
In order to obtain full lipid hydration, the liposomal suspension is left overnight at 4 ºC. 
The lipid-film hydration method can be used for all different kinds of lipid mixtures19. 
i. Micro-emulsification method: 
   An equipment called as microfluidizer is used to prepare small vesicle 
from concentrated lipid suspension. The lipids can be introduced into the fluidizer as a 
                                                                                                                    INTRODUCTION 
S.B.C.P          Page No. 14 
suspension of large MLVs. This equipment pumps the suspension at very high pressure 
through the 5 mm screen. Then it is forced long micro channel, which direct two streams 
of fluid collide together at right angle and very high velocity. The fluid collected can 
be recycled through the pump and interaction chamber until vesicles of spherical 
dimension are obtain20. 
 
iii. Sonication 
   Sonication is perhaps the most extensively used method for the 
preparation of SUV. Here, MLVs are sonicated either with a bath type sonicator or a 
probe sonicator under a passive atmosphere. The main disadvantages of this method are 
very low internal volume/encapsulation efficacy, possible degradation of phospholipids 
and compounds to be encapsulated, elimination of large molecules, metal pollution 
from probe tip, and presence of MLV along with SUV. There are two sonication 
techniques21. 
a. Probe sonication: The tip of a sonicator is directly engrossed into the liposome 
dispersion. The energy input into lipid dispersion is very high in this method. The 
coupling of energy at the tip results in local hotness; therefore, the vessel must be 
engrossed into a water/ice bath. Throughout the sonication up to 1 h, more than 5% of 
the lipids can be de-esterified. Also, with the probe sonicator, titanium will slough off 
and pollute the solution21. 
b. Bath sonication:  The liposome dispersion in a cylinder is placed into a bath 
sonicator. Controlling the temperature of the lipid dispersion is usually easier in this 
method, in contrast to sonication by dispersal directly using the tip. The material being 
sonicated can be protected in a sterile vessel, dissimilar the probe units, or under an 
inert atmosphere21 
 
iv. French pressure cell: 
   French pressure cell involves the extrusion of MLV through a small 
orifice. An important feature of the French press vesicle method is that the proteins do 
not seem to be significantly pretentious during the procedure as they are in sonication. 
An interesting comment is that French press vesicle appears to recall entrapped solutes 
significantly longer than SUVs do, produced by sonication or detergent removal. The 
method involves gentle handling of unstable materials. The method has several 
advantages over sonication method. The resulting liposomes are rather larger than 
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sonicated SUVs. The drawbacks of the method are that the high temperature is difficult 
to attain, and the working volumes are comparatively small (about 50 mL as the 
maximum)8. 
 
v. Membrane extrusion: 
   In this method, MLVs is reduced by passing them through a membrane 
filter of defined bore size. There are two types of membrane filter. The tortuous bath 
type and the nucleation track type. The former is used for sterile filtration. In this 
random bath arises between the criss cross fibres in the matrix. Liposomes that are 
larger than the channel diameter get struck when one tries to pass them though such 
membrane. The nucleation track is composed of thin continuous sheet of polycarbonate. 
They will offer less resistance to passage of liposomes as these consist of straight sided 
pore holes off exact diameter bored from one side to another. This method can be used 
to process both LUVs and MLVs18. 
 
vi. Dried reconstituted vesicles: 
   In DRV method freeze drying of a dispersion of empty SUVs are to be 
done and then dispersion of it with the aqueous fluid containing the material to be 
entrapped. This leads to a hydration of solid lipids in finely reduced sized form. Though, 
the step of freeze-drying is introduced to freeze and lyophilize a performed SUVs 
dispersion rather than to dry the lipids from an organic solution. This leads to an ordered 
membrane structure as compared to random matrix structure, which on addition of 
water can rehydrate, fuse and reseal to form vesicles with a high encapsulation 
efficiency. The water soluble hydrophillic materials to be entrapped are added to the 
dispersion which are empty SUVs and they are dried together, so the material for 
inclusion is present in the dried precursor lipid before the final step of addition of 
aqueous medium18. 
 
vii. Freeze-thawed liposome: 
   SUVs are rapidly frozen and thawed slowly. The short-lived sonication 
disperses aggregated materials to LUV. The creation of UV is as a result of the fusion 
of SUV throughout the processes of freezing and thawing. This type of synthesis is 
strongly inhibited by increasing the phospholipid concentration and by increasing the 
ionic strength of the medium. The encapsulation efficacies from 20% to 30% were 
obtained8. 
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2. Solvent Dispersion Method: 
  In these methods lipids are first dissolved in an organic solution and then 
brought into contact with aqueous phase containing materials to be entrapped within 
liposome. At the interface between the organic and the aqueous phases the 
phospholipids align themselves to form a monolayer, which is important step to form 
the bilayer of liposome20. 
 
i. Ether injection (solvent vaporization)8: 
  A solution of lipids dissolved in diethyl ether or ether-methanol mixture is 
gradually injected to an aqueous solution of the material to be encapsulated at 55°C to 
65°C or under reduced pressure. The consequent removal of ether under vacuum leads 
to the creation of liposomes. The main disadvantages of the technique are that the 
population is heterogeneous (70 to 200 nm) and the exposure of compounds to be 
encapsulated to organic solvents at high temperature. 
 
ii. Ethanol injection8: 
  A lipid solution of ethanol is rapidly injected to a huge excess of buffer. The 
MLVs are at once formed. The  is advantages of the method are that the population is 
heterogeneous (30 to 110 nm), liposomes are very dilute, the removal all ethanol is 
difficult because it forms into azeotrope with water, and the probability of the various 
biologically active macromolecules to inactivate in the presence of even low amounts 
of ethanol is high. 
 
iii. Double emulsion method: 
In this process, an active ingredient is initially dissolved in an aqueous phase 
(w1) which is then emulsified in an organic solvent containing polymer to form a 
primary w1/o emulsion. This primary emulsion is then mixed in an emulsifier which 
also consist of aqueous solution (w2) to form a w1/o/w2 double emulsion. The 
extraction of the solvent leaves microspheres in the aqueous external phase, making it 
possible to seperate them by filtering or centrifuging18. 
 
iv. Reverse phase evaporation method: 
   The lipid mixture is added to a round bottom flask and the solvent is 
removed under reduced pressure by a rotary evaporator. The system is purged with 
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nitrogen and lipids are re-dissolved in the organic phase which is the phase in which 
the reverse phase vesicle will form. Diethyl ether and isopropyl ether are the usual 
solvents of choice. After the lipids are re-dissolved the emulsion are obtained and then 
the solvent is removed from an emulsion by evaporation to a semisolid gel under 
reduced pressure. Phosphate buffer saline or citric-Na2HPO4 buffer is added to aqueous 
phase with aim to improve the efficiency of liposome formulations. The formation of 
liposomes is allowed by continued rotary evaporation of the organic solvents under 
vacuum. Non encapsulated material is then removed. The resulting liposomes are called 
reverse phase evaporation vesicles (REV). This method is used for the preparation of 
LUV and OLV formulation and it has the ability to encapsulate large macromolecules 
with high efficiency13,19. 
 
v. Stable pluri lamellar vesicles: 
   This method of pluri lamellar vesicle preparation followed by formation 
of water-in-organic phase dispersion with an excess of lipid which further introduce to 
drying under continued bath sonication with an irregular stream of nitrogen. SPLVs 
require a large aqueous core, the common of the entrapped aqueous medium being 
located in the compartment in between adjacent lamellae. The percent entrapment 
normally ranges around 30%18. 
 
3. Detergent Removal Method: 
   In this method the phospholipids are brought into close contact with the 
aqueous phase via detergents, which associate with phospholipids molecules. The 
structures formed as a result of this association are known as micelles. They are 
composed of several hundreds of component molecules. The concentration of detergent 
in water at which micelles start to form is called CMC. Below CMC the detergent 
molecule exist in free solution. As the detergent molecule is dissolved in water at 
concentration higher than the CMC, micelle form in large amounts. As the 
concentration of detergent added is increased more amount of detergent is 
incorparorated into the bilayer, until a point is reached where conversion from lamellar 
form to spherical micellar form take place. As detergent concentration is further 
increased, the micelles are reduced in size20. 
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i. Dialysis:  
   Detergents are mainly soluble in both aqueous as well as organic media 
and there is an equilibrium within the detergent molecules in the water phase, and in 
the lipid environment of the micelle. The CMC can give an indication to the position of 
this equilibrium. Upon reducing the concentration of detergent in the whole aqueous 
phase, the molecules of detergent can be washed away from mixed micelle by dialysis. 
The action of egg PC with a 2:1 molar ratio of sodium cholate followed by dialysis 
which lead to the formation of vesicles (100nm). A commercial version of the dialysis 
system is available under the trade name LIPOPREPTM ( Diachema AG, 
Switzerland)18. 
 
ii. Column Chromatography: 
  Phospholipids in the form of either sonicated vesicles or as a dry film, at a molar 
ratio of 2:1 with deoxycholate form UV of 100nm. Deoxycholate remove using column 
chromatography .This could be done by the passing the dispersion over a Sephadex G-
259 column presaturated by constitutive lipids and preequilibrated using hydrating 
buffer18. 
 
iii. Dilution: 
  Upon dilution of aqueous mixed micellar solution of detergent and 
phospholipids with buffer, the micellar size and the polydispersity increase 
fundamentally, and as the system is diluted beyond the mixed micellar phase boundary, 
a spontaneous transition from poly-dispersed micelles to vesicles occurs8. 
 
B. ACTIVE LOADING: 
  The exploitation of liposomes as drug delivery system is encouraged with the 
advancement of well-organized encapsulation procedures. The membrane from the 
lipid bilayer is in general impermeable to ions and larger hydrophilic molecules. Ions 
transport can be synchronized by the ionophores though permeation of neutral and 
weakly hydrophobic molecule can be inhibited by concentration gradients.  
  A few weak acid or bases yet, can be transported throughout the membrane 
because of various transmembrane gradient, such as electric, ionic (pH) or specific salt 
(chemical potential) gradient. Some method exist for improved incorporation of drugs, 
including remote (active) loading method which load drug molecules into preformed 
liposome using pH gradient and potential difference across liposomal membrane.                
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A concentration variation in proton concentration across the membrane of liposomes 
can drive the loading of amphipathic molecule18.  
 
Active loading methods have the following benefit over passive encapsulation 
Technique 
a) It will lead to high encapsulation efficiency and capacity.  
b) Using these method leakage of the encapsulated compounds can be reduced.  
c) “Bed side” loading of drugs therefore limiting loss of retention of drugs by 
diffusion, or chemical degradation while storage. 
d) These process is flexible for constitutive lipid, as drug is loaded after the formation 
of carrier unit.  
e) It also reduce the safety hazard by avoiding biologically active compounds in the 
preparation step during dispersion.  
f) The transmembrane pH gradient may be occured by various method. Based upon 
the nature of drug to be encapsulated18. 
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AIM AND OBJECTIVE OF THE WORK 
The aim of the present study was to formulate Metformin HCl liposomes for a 
sustained drug delivery system. The liposomes was prepared by two different methods 
(physical dispersion method and ether injection method) and then it was evaluated for 
various parameters.  
The objective of the study is follows as. 
To subjugate inherent defects associated with conventional dosage form of  
Metformin HCl, by formulating oral Metformin HCl liposomes which have the 
following advantages. 
1. Reduce the dose and dosing frequency.  
2. Minimize the side effect. 
3. Prolong the action of drug. 
4. Provide sustained drug release. 
5. Better patient compliance. 
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PLAN OF WORK 
 The present work carried out to formulate sustained release 
Metformin HCl liposomes and it was planned to evaluate the various parameters as 
outlined below: 
 To determine the solubility of Metformin HCL in water, methanol and pH 6.8 
 Drug-excipients interaction studies by using FT-IR. 
 To formulate Metformin HCl liposomes by using cholesterol and lecithin as 
encapsulated lipids bilayer in various ratio such as 1:1, 1:2 and 1:3 by two 
different method namely physical dispersion method and ether injection 
method. 
 To evaluate the prepared liposomes for following parameters: 
i. Drug entrapment efficiency. 
ii. Morphological analysis. 
iii. Particle size analysis. 
iv. In vitro drug release studies. 
v. Stability studies. 
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REVIEW OF LITERATURE 
Dina Fathalla et al23., formulated and evaluated liposomal gels for 
sustained ocular delivery of  latanoprost  using two different methods, namely  thin film 
hydration and reverse phase evaporation techniques.  The objective of their work was 
to develop a liposome-based delivery system for the sustained ocular delivery of 
latanoprost, a prostaglandin analog commonly used in the management of glaucoma. 
Latanoprost was incorporated into different liposomes that were evaluated using variety 
of techniques. Selected liposomes were incorporated into different gels and their 
viscosity and drug release kinetics were evaluated. Optimal liposomal gels were 
evaluated in vivo in rabbits’ eyes for their irritation potential and ability to reduce 
intraocular pressure. Fourier transform infrared and differential scanning calorimetry 
studies confirmed the interaction between the drug and different excipients in the 
vesicles, which resulted in drug encapsulation efficiency ≥ 90%. Drug encapsulation 
efficiency increased with the drug/lipid ratio and encapsulation efficiency ~98% was 
obtained at drug/lipid ratio of 50%. Vesicles incorporated into Pluronic® F127 gel had 
sustained drug release where ~45% of the encapsulated drug was released in 2 days. 
Latanoprost liposomal gels had neither irritation nor toxic effects on the rabbits’ eyes. 
Further, they had a sustained reduction in the rabbit’s intraocular pressure over a period 
of 3 days, which was significantly longer than that achieved by the commercial 
latanoprost eye drops. 
 
S. Rathod and S. G. Deshpande24., designed and evaluated prolonged release 
drug delivery system of pilocarpine nitrate was made by optimizing thin layer film 
hydration method. Egg phosphatidylcholine and cholesterol were used to make 
multilamellar vesicles. Effects of charges over the vesicles were studied by 
incorporating dicetylphosphate and stearylamine. Various factors, which may affect the 
size, shape, encapsulation efficiency and release rate, were studied. Liposomes in the 
size range 0.2 to 1 μm were obtained by optimizing the process. Encapsulation 
efficiency of neutral, positive and negatively charged liposomes were found to be 
32.5%, 35.4% and 34.2%, respectively. Biological response in terms of reduction in 
intraocular pressure was observed on rabbit eyes. Pilocarpine nitrate liposomes were 
lyophilized and stability studies were conducted. 
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Thi Lan Nguyen et al25., developed and in vitro evaluated liposomes using soy 
lecithin to encapsulated paclitaxel. Paclitaxel liposomes were prepared by thin film 
method using soy lecithin and cholesterol and then were characterized for their 
physiochemical properties such as particle size, polydispersity index, zeta potential, and 
morphology. The results indicated that paclitaxel liposomes were spherical in shape 
with a dynamic light scattering (DLS) particle size of 131 ± 30.5 nm. Besides, paclitaxel 
was efficiently encapsulated in liposomes, 94.5 ± 3.2% for drug loading efficiency, and 
slowly released up to 96 h, compared with free paclitaxel. More importantly, cell 
proliferation kit I (MTT) assay data showed that liposomes were biocompatible 
nanocarriers, and in addition the incorporation of paclitaxel into liposomes has been 
proven successful in reducing the toxicity of paclitaxel. As a result, development of 
liposomes using soy lecithin may offer a stable delivery system and promising 
properties for loading and sustained release of paclitaxel in cancer therapy. 
 
Ravindra kamble et al26., developed and characterized liposomal  drug 
delivery  system  for Nimesulide by various techniques such as ethanol evaporation and  
rotary evaporator method.  The encapsulation of Nimesulide into liposomes 
significantly improves their properties. In spite of the numerous advantages of using 
liposomes as carriers to deliver Nimesulide over the  free form of the drug, in vitro 
studies of liposome‐encapsulated Nimesulide have been mainly focused on evaluation 
of better method of  Nimesulide  liposomes  which  have  high  drug  entrapment,  
vesicle  size and drug  release.   The average particle size, percent drug entrapment, 
drug release at the end was found to be 270‐703µm, 49‐58 %, and 65.71 % at 9 hours 
in case of ethanol injection method while in case of rotary evaporator it was found to 
be 1‐12µm, 69‐86% and 76.97%  at 9 hours respectively. The Zeta potential for 
Nimesulide loaded liposomes of ethanol injection method (batch‐ 1) and rotary 
evaporator method (batch – 3) were ‐21.23 and ‐26.78 mV respectively. The result 
obtained in this study rotary evaporator technique was better for Nimesulide liposomes 
preparation on the basis of stability, drug entrapment efficiency and ethanol injection 
method was better on the basis of small size of liposomes and sustains release of drug 
when compared to rotary evaporator method and pure drug.  
 
Devi R et al27., prepared and evaluated the topical liposomes of Fluconazole by 
thin film hydration technique using different ratios of soya phosphotidyl choline and 
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cholestrol. The in-vitro diffusion study was carried out by dialysis membrane using 
both open ended tube. The study was carried out in 40 ml of phosphate buffer solution 
pH 7.4. The percentage cumulative release from the optimized batch i.e. F7 with drug: 
lecithin: cholesterol ratio 1: 10: 5, found to be 75.02% release in 8 hours. The magnitude 
of drug retention within the vesicles on storage under defined conditions ultimately 
governs shelf life of the developed formulations. Liposomes showed an increasing 
vesicle size in accelerated temperature but no significance changes at 4±2°C has 
observed in storage studies for two months. 
 
Bahareh Sabeti et al28., developed and characterized  liposomal doxorubicin 
hydrochloride with palm oil by freeze thaw method. Their study focuses on the 
utilization of palm oil in formulating liposomal doxorubicin for minimizes toxicity and 
enhances target delivery actions by replacing phosphatidylcholine with 5% and 10% 
palm oil content. Liposomes were formed using the freeze thaw method, and 
Doxorubicin was loaded through pH gradient technique and characterized through in 
vitro and ex vivo terms. Based on TEM images, large lamellar vesicles (LUV) were 
formed, with sizes of 438 and 453 nm, having polydispersity index of 0.21 ± 0.8 and 
0.22 ± 1.3 and zeta potentials of about −31 and −32 mV, respectively. In both 
formulations, the entrapment efficiency was about 99%, and whole Doxorubicin was 
released through 96 hours in PBS (pH = 7.4) at 37∘ C. Comparing cytotoxicity and 
cellular uptake of LUV with CaelyxR on MCF7 and MDA-MBA 231 breast cancer cell 
lines indicated suitable uptake and lower IC50 of the prepared liposomes. 
 
Ehab I. Taha et al29., designed and evaluated liposomal colloidal systems for 
ocular delivery of ciprofloxacin. The aim of their study was enhance occular drug 
delivery for protective mechanism of eye is limited the bioavailability of drug. In this 
study several liposomal formulations containing ciprofloxacin have been formulated 
using reverse phase evaporation technique with final dispersion of pH 7.4. Different 
types of phospholipids including Phosphatidylcholine, Dipalmitoyl 
phosphatidylcholine and Dimyristoyl-sn-glycero-3-phosphocholine were utilized. The 
effect of formulation factors such as type of phospholipid, cholesterol content, 
incorporation of positively charging inducing agents and ultrasonication on the 
properties of the liposomal vesicles was studied. Bioavailability of selected liposomal 
formulations in rabbit eye aqueous humor has been investigated and compared with that 
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of commercially available ciprofloxacin eye drops (Ciprocin). Pharmacokinetic 
parameters including Cmax, Tmax, elimination rate constant, t1/2, MRT and AUC0–1, 
were determined. The investigated formulations showed more than three folds of 
improvement in ciprofloxacin ocular bioavailability compared with the commercial 
product. 
 
Eskandar Moghimipour et al30., formulated and evaluated topical liposomal 
gel of triamcinolone acetonide. Liposomes containing triamcinolone acetonide were 
prepared using thin film method. The aim of their study was to formulate and evaluate 
liposomal vesicles loaded with triamcinolone acetonide. The quantities of lecithin and 
cholesterol were changed to enhance the encapsulation of the drug. Carbomer 940 was 
used as gel base and four different gel formulations including hydroalcoholic gel, MLV 
liposomal gel, SUV liposomal gel and blank MLV gel containing free drug were 
prepared. The release profile of triamcinolone acetonide was determined using dialysis 
membrane method. Liposomes were also characterized by optical microscope and their 
particle size was also determined. Formulation containing lecithin: drug: cholesterol 
(100: 10: 10) having about 90.05% encapsulation was selected as the best formulation 
and the results of release showed SUV liposomal gel has the most regular and the least 
interaction between the drug and polymer. Results of particle size determination 
showed 50% of MLV and SUV liposomes had diameter below 33.80 μm and 22.09 μm, 
respectively. The results of characterization of the vesicles indicated the potential 
application of triamcinolone acetonide loaded liposome as carrier system.  
 
B. R. Srinivas Murthy et al31., formulated and evaluated liposomes loaded with 
mupirocin. Their study aimed at developing and optimising liposomal formulation of 
Mupirocin, a broad spectrum antibiotic of maximum therapeutic efficacy with minimal 
side effects by lipid film hydration technique using various ratios of soya lecithin and 
cholesterol. Upon pre-formulation studies and optimization, the various formulations 
(of varying proportions) were prepared and subjected for various physico-chemical 
evaluation studies i.e., morphology, particle size, drug entrapment efficiency, in-vitro 
drug release, release kinetics and stability studies. Among five formulations (F1- F5) 
F4 formulation emerged as the most satisfactory formulation in all the evaluation 
parameters. F4 showed a maximum drug entrapment of 71.72%, average particle size 
was 18.3 μm, maximum percentage yield 89.06%. The liposomes were found to be 
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stable during their stability studies when stored at different temperatures. They 
concluded that Mupirocin can also be loaded in liposomal carriers which found to be 
effective, stable. 
 
Behzad Sharif Makhmalzadeh et al32., prepared and evaluated  mafenide 
acetate liposomal formulation as eschar delivery system. Liposome formulations were 
prepared by two different methods such as Solvent evaporation method and 
microencapsulation vesicle (MCV) method. The prepared liposomes undergoes 
experimental design and data analysis. Drug/lipid ratio, hydration time, aqueous phase 
volume and homogenizer rpm were considered as independent variable, on the other 
hand, liposome size, drug loading, stability, drug release and skin permeability 
parameters as responses. The results demonstrate that liposome were multilamellar and 
multivesicular. Particle size and drug loading percentage of MCV liposome indicated 
burst sustained release profile. Burst effect in solvent evaporation liposome was more 
than MCV liposome. In their conclusion, solvent evaporation liposome improved 
mafenide acetate partitioning through rat skin and decrease diffusion coefficient with 
increase particle size of liposome. 
 
Srinivas Lankalapalli  et al33., prepared and evaluated liposome formulations 
for poorly soluble drug Itraconazole by complexation. Beta cyclodextrin and Hydroxy 
propyl beta cyclodextrin inclusion complexes with Itraconazole were prepared by 
kneading method/ solvent injection method and these complexes were incorporated in 
the aqueous phase of the liposomes to prepare Itraconazole liposomes. Factor such as 
ratio of lipids employed, drug:lipid ratio, etc were fine tuned and optimized to achieve 
maximum entrapment of the Itraconazole in the aqueous phase. The prepared liposomes 
are characterized by optical microscopy, scanning electron microscopy, particle size 
determination, encapsulation efficiency and also evaluated by using FTIR spectroscopy 
and in-vitro diffusion studies by using dialysis membrane. . The drug content was in 
the range of 94.78 % w/w to 101.81 % w/w for the liposome formulations. The 
encapsulation efficiency was found to be 37.99 % to 55.01 %. The percentage drug 
release was found to be 17.25% to 39.62%. The increase in the solubility of Itraconazole 
with cyclodextrin complexes in comparision with plain drug is an indubitable advantage 
of this approach. 
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Anayatollah Salami et al34., formulated and evaluated liposomes for 
transdermal delivery of Celecoxib. Liposomes were prepared by thin film method using 
soya lecithin and cholesterol. Physicochemical characteristics of the liposomes such as, 
particle size, drug encapsulation efficiency, drug release and in vitro skin permeability 
through rat skin were evaluated using Franz diffusion cells were determined. The results 
showed that the maximum drug encapsulation efficiency was 43.24%. Drug release 
profile showed that 81.25% of the drugs released in the first 24 hours of the experiment. 
The decrease of lecithin increased values. Particle sizes of the formulations ranged from 
0.117 to 1.123 µm. Jss, Dapp and P parameters in L - 8 formulations were 29.18, 60.95, 
and 3.21 times higher than those of saturated water solution of celecoxib, respectively. 
The results of vesicles characterization indicated the potential application of celecoxib 
loaded liposome as carrier system. In conclusion, the components such as lecithin and 
cholesterol, and vortex time in liposomal formulations have an essential role in the 
physicochemical properties and celecoxib permeability through rat skin. 
 
U. D. Shivhare et al35., formulated and evaluated liposome formulation of 
pentoxifylline.  Liposomes were prepared by physical dispersion method using different 
ratio of lipids. In evaluation study, the effect of the varying composition of lipids on the 
properties such as encapsulation efficiency, particle size and drug release were studied. 
Phase transition study was carried out to confirm the complete interaction of 
pentoxifylline with bilayer structure of liposome. Moreover, the release of the drug was 
also modified and extended over a period of 8 h in all formulations. The average particle 
size, percent drug entrapment, drug release at the end was found to be 6.24 - 15.07 µm, 
29.64 ‐ 48.92 %, and 90.0- 99.23 % at 8 hours. In concluison, release of the drug from 
the most satisfactory formulation was evaluated through dialysis membrane to get the 
idea of drug release.  
 
Yan Chen et al36., Prepared Curcumin-Loaded Liposomes and evaluated their 
skin permeation and pharmacodynamics. Liposomes were prepared by the conventional 
film method. Soybean phospholipids (SPC), egg yolk phospholipids (EPC), and 
hydrogenated soybean phospholipids (HSPC) were selected for the preparation of 
different kinds of phospholipids composed of curcumin-loaded liposomes: C-SPC-L 
(curcumin-loaded SPC liposomes), C-EPC-L (curcumin-loaded EPC liposomes), and 
C-HSPC-L (curcumin-loaded HSPC liposomes). The physical properties of different 
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lipsomes were investigated as follows: photon correlation spectroscopy revealed that 
the average particle sizes of the three types of curcumin-loaded liposomes were 82.37 
± 2.19 nm (C-SPC-L), 83.13 ± 4.89 nm (C-EPC-L), and 92.42 ± 4.56 nm (C-HSPC-L), 
respectively. The encapsulation efficiency values were found to be 82.32 ± 3.91%, 
81.59 ± 2.38%, and 80.77 ± 4.12%, respectively. An in vitro skin penetration study 
indicated that C-SPC-L most significantly promoted drug permeation and deposition 
followed by C-EPC-L, C-HSPC-L, and curcumin solution. Moreover, C-SPC-L 
displayed the greatest ability of all loaded liposomes to inhibit the growth of B16BL6 
melanoma cells. Therefore, the C-SPC-L were chosen for further pharmacodynamic 
evaluation. A significant effect on antimelanoma activity was observed with C-SPC-L, 
as compared to treatment with curcumin solution in vivo. Their results suggest that C-
SPC-L would be a promising transdermal carrier for curcumin in cancer treatment. 
 
Xiang-qi QIN et al37., prepared a novel transdermal preparation of liposomal 
brucine (LB) and investigate its pharmaceutical/pharmacodynamic characterization. LB 
was prepared by a modified ethanol-dripping method. Its drug encapsulation efficiency 
(EE), particle size, in vitro release, and skin permeation were studied. Furthermore, a 
safety evaluation and pharmacodynamic analysis of LB, including acute dermal 
toxicity, skin irritation, and analgesic and anti-inflammatory effects were investigated. 
The EE of LB was 72% and the mean particle size of the liposomes was 55.4 nm. The 
in vitro release profile indicated that less than 68% of the encapsulated brucine was 
released in 10 h. A skin permeation study showed that compared with the free brucine, 
LB exhibited higher cumulative drug permeation through the skin and lower drug 
accumulation in skin tissue, indicative of an obvious promotion of skin permeation with 
liposomal encapsulation. The acute dermal LD50 of LB was greater than 100 mg/kg 
(brucine content) and skin irritation tests revealed that LB had no irritation to both 
integrity and broken skin. A pharmacodynamic evaluation of LB was performed by 
xylene-induced mouse ear edema test and acetic acid-induced writhing test at the 
dosage of 1.5, 3, and 6 mg/kg, respectively. The results showed that anti-inflammatory 
activities and analgesic effects of brucine encapsulated were significantly higher than 
that of the free brucine (P<0.01). It can be proposed that LB prepared here could 
represent a safe, effective and promising transdermal formulation for analgesic and 
anti-inflammatory effects. 
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P.Divakar et al38., formulated and in vitro evaluated liposomes containing 
metformin hydrochloride. Liposomal suspensions were prepared using film hydration 
technique using varying concentrations of phosphatidylcholine and cholesterol and 
optimize the ideal combination for required drug release. Liposomal formulations were 
evaluated for particle size, drug entrapment and in-vitro drug release studies. The 
percentage drug release at the end was found to be 64.0- 83.0 % at 4 hours. Drug 
excipient compatibility was determined by using U.V spectroscopy, FT-IR spectral 
studies. The results of in vitro drug release studies showed that release from liposomal 
formulation was slow and sustained for >12 hrs period. The formulations followed first 
order kinetics and release mechanism was non-fickian diffusion from all the 
formulations. 
 
Satyavathi K et al39., formulated and in-vitro evaluated liposomal drug delivery 
system of cabazitaxel. Cabazitaxel liposomes were prepared by thin film hydration 
technique using lecithin, cholesterol, and Tween 80. Six formulations of liposomes 
were evaluated for physico chemical properties and in vitro drug release. The 
compatibility of drug with other ingredients was checked by FTIR studies. The prepared 
liposomes were characterized for surface morphology by SEM analysis, Percentage 
drug entrapment efficiency, Particle size, and Zeta potential analysis. The average 
particle size, poly dispersive index, percentage drug entrapment efficiency and zeta 
potential analysis as found to be 317 nm to 564 nm, 0.632 to 0.762,  78.39% to 82.96% 
and -15.2mV to -20.9mV .The in-vitro drug release for optimized formulation F2 
followed zero-order release kinetics. F2 was formulated using 270 mg lecithin and 30 
mg cholesterol and 0.5 ml of Tween 80 with an objective to achieve a linear release 
profile for 24 hr. There was no initial burst release, with 5.68% of drug released during 
the first hour and release was extended up to 24 hrs. Stability studies at different 
temperatures were conducted and maximum drug retention was found at refrigerated 
temperature 4ºC. 
 
Anjana ashok adhyapak, and Babasaheb gangadhar desai40., formulated 
and evaluated liposomal transdermal patch for targeted drug delivery of tamoxifen 
citrate for breast cancer.  Liposomes were formulated by solvent evaporation method 
using poly (sebacic acid-co-ricinoleic acid) in varying ratios and evaluated for particle 
size, drug loading, entrapment efficiency, transmission electron microscopy, 
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differential scanning calorimetry, and X-ray diffraction. Formulated tamoxifen-loaded 
liposomes were finally incorporated into transdermal patch and evaluated for thickness 
drug content, moisture content, moisture uptake, folding endurance, tensile strength 
diffusion coefficient, permeability coefficient, in vitro permeation, and skin irritation. 
Optimized transdermal patches were tested for its pharmacokinetic and 
pharmacodynamics parameters. The average particle size, percentage drug entrapment 
efficiency and percentage drug release was found to be 412-543nm, 90.32 -93.33%. It 
can be concluded Optimized patch formulation F3 was found to have the best release 
profile when compared to other patches with no skin irritation. Pharmacokinetic and 
pharmacodynamics profile of formulated patch confirms its advantage over other 
conventional existing formulations. 
 
Shruthi M V et al41, formulated and evaluated proliposomal gel containing 
metformin hydrochloride using mannitol as a water soluble carrier. Proliposomes of 
Metformin hydrochloride were prepared by thin film hydration technique by varying 
the composition drug, manitol, soya lecithin and cholesterol. Proliposome formulations 
were characterized for compatibility, vesicle size, % Drug content, % Entrapment 
efficiency, Surface morphology, Surface charge, invitro drug release and stability 
studies. The proliposomal gel was prepared for optimized proliposomal formulation F4 
by incorporated into 1% Carbopol gel. The in vitro drug release and in vivo skin 
irritation study and hypoglycemic activity were carried out for the gel F4. Drug and 
physical mixture were characterized by FTIR, the result of IR study showed that no 
interaction between drug and polymers and other formulation parameters of formulated 
proliposomes and proliposomal gel are evaluated which showed better results. 
Proliposomal gel F4 was proved nonirritant and showed better stability, more 
hypoglycemic effect as compared to oral formulation because it provide reduction in 
blood glucose level with controlled manner upto 24 hrs. Hence, Proliposomes drug 
delivery system was better choice for sustained release of drug through topical drug 
delivery. 
 
Sangeetha S. S. and Roopa Karki42., formulated and evaluated liposomes in 
carbopol gels for mixed vaginal infections. The combination of voriconazole and 
metronidazole were selected as model drugs for mixed vaginal infections. Multi 
lamellar liposomes composed phosphatidylcholine and cholesterol along with 
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combination of drugs was prepared by the thin film hydration method. The prepared 
liposome were characterized for FT-IR, size distribution, entrapment efficiency, in vitro 
release study in simulated vaginal fluid and stability studies. The liposomes were loaded 
to carbopol gel. The liposomes loaded carbopol gels were evaluated for in vitro drugs 
release study and compared with control gel. FTIR study indicated that there is no 
significant chemical interaction between the components. The cumulative percent 
release from liposomal gels FL1 was found to be 69.90% for metronidazole and 56.02 
% for voriconazole. In vitro release studies of liposomes incorporated in the carbopol 
gel have shown a prolonged release of entrapped metronidazole and voriconazole 
compared to control gel. Stability studies showed that the vesicles were stable in 
refrigerated temperature (4°C) for 60 days without significant differences in drug 
entrapment. 
 
Krishna Mohan Chinnala and Rabinarayan Panigrahy43., formulated and 
evaluated of acyclovir liposomes. The liposomes were prepared by rotary flash 
evaporation method and thin film hydration technique using different ratios of 
phospholipids and cholesterol with a desired amount of drug. The percentage 
entrapment efficiency was determined and maximum entrapment efficiency was found 
to be 99%. The optimized batches were found to have good entrapment efficiency and 
it was proved that as the concentration of the cholesterol increased the particle size also 
increased and entrapment efficiency decreased. In formulation TB1 the ratio of 
cholesterol and lecithin is 1:1 is selected as optimized formulation based on entrapment 
efficient and diffusion studies Optimized formulation was evaluated for particle size 
analysis and zeta potential.  FTIR studies were done on the pure drug and physical 
mixture of drug and polymers. From FTIR spectra of the drug and physical mixture it 
was found that there is no significant interaction. Zeta potential analysis was done for 
optimized formulation TB1. Average zeta potential and charge on the liposome was 
determined. The value was -20 Mv which indicates that the surface of liposomes is 
dominated by the anions and proved that prepared liposome have sufficient charge to 
avoid aggregation of vesicles. It can be concluded that as the concentration of the 
cholesterol increased the particle size also increased and entrapment efficiency 
decreased. 
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Sunitha Sampath et al44., prepared and evaluated liposome entrapped hydrogel 
complex systems of itraconazole for enhanced transdermal permeation. The liposomes 
were prepared by thin flim hydration method. The complex systems were prepared by 
incorporating drug liposome consisting of biocompatible lipid, into carbopol to form 
hydrogel. The systems were evaluated for encapsulation efficiency, particle size, zeta 
potential and ex vivo release behavior for skin permeability. FT-IR studies were done 
to find for any drug excipient interactions. The particle size was ranging from 94.2 nm 
to 104.8 nm with low PdI indicating the formation of monodisperse system. The % of 
drug released from the formulation was ranging from 48.04 % to 99.92 % in 24 h. In 
terms of skin permeability, complex liposomal hydrogel has proved to have greater skin 
permeation compared to simple liposomal system, simple hydrogel system and the plain 
drug suspension (485.49, 362.06, 226.03 and 172.25 μg/cm2 /h1). From the release 
kinetics concluded the drug is releasing by diffusion mechanism and also due to erosion 
of the gelling agent. It was found that liposome in hydrogel complex systems improved 
skin permeability of the drug when compared to control with high flux and high 
permeability coefficient. These results indicate that liposome in hydrogel systems can 
function as probable drug delivery systems to enhance transdermal permeation of the 
water insoluble itraconazole for treating the topical infections. 
 
Dr. Khaja Pasha and Dr. Shahana Banu45., formulated and evaluated 
glimepiride liposomal drug delivery system. Liposomes were prepared by physical 
dispersion method using different ratio of lipids. In evaluation study the effect of the 
varying composition of lipids on the properties such as encapsulation efficiency, 
particle size and drug release were studied. Phase transition study was carried out to 
confirm the complete interaction of Glimepiride with bilayer structure of liposome. 
Moreover, the release of the drug was also modified and extended over a period of 8 h 
in all formulations. F1 emerged as the most satisfactory formulation in so far as its 
properties were concerned. Further, release of the drug from the most satisfactory 
formulation (F1) was evaluated through dialysis membrane to get the idea of drug 
release. 
 
Akshay Singha Roy et al46., designed, formulated and evaluated liposome 
containing isoniazid. Liposome of isoniazid was made by thin layer film hydration 
method. Six batches of liposomes were prepared based on the different weight ratio of 
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L-α-phosphatidylcholine and cholesterol. Differential scanning calorimetry (DSC) 
study conducted to study in any incompatibility. The prepared liposomes were 
evaluated by particle size analysis, entrapment efficiency, release study and stability 
study. Particle sizes were determined from the scanning electron microscopy (SEM) 
photographs. When particle frequencies were plotted against particle diameter in the 
histogram, it showed that F1 batch had a skewed distribution towards smaller liposomes 
while F6 shows a proper bell-shaped curve with a mean at 225 µm. The percentage 
entrapment efficiency was found to be 4.19 ± 0.12 to 8.99 ± 0.15% . From the release 
profile, it was seen that F1 batch was fastest and F6 was slowest to release the drug. 
The satisfactory batch F1 was packed in Eppendorf tube and stored at 4°C temperature 
for one month. At the end of one month, the samples were analyzed for their physical 
properties, drug entrapment and in vitro release profile. The percentage release was 
found to be 96.5 ± 3.2 after 4 hr.  The F1 batch showed most promising results compared 
to other. No significant change was found during one month’s stability study of final 
batch (F1). 
 
M. P. Jadhav et al47., formulated and evaluated long circulating liposomes for 
amphotericin B.  Liposomes were prepared by simple film hydration method. The 
formulation was optimized using 23 factorial designs. Pegylated liposomal formulation 
showed favorable results with reference to particle size (247.33±9.60 nm), percent 
entrapment efficiency (94.55±3.34%). TEM studies revealed that the liposomes were 
essentially spherical, hollow, and appeared like powder puff structures. From DSC 
study it was concluded that the pegylated formulation containing Amp B showed better 
stability and membrane integrity of the formulation. During the stability studies the 
formulation was found to be stable. When subjected to gamma scintigraphy kinetic 
tracer studies the formulation showed longer residence time in the blood in BALB/C 
mice. 
 
Toshimasa Tsukamoto et al48, prepared bromfenac-loaded liposomes modified 
with chitosan for ophthalmic drug delivery and evaluated physicochemical properties 
and drug release profile.  Bromfenac (BRF)-loaded liposomes were prepared using the 
calcium acetate gradient method. Liposome sizes and encapsulation efficiencies were 
optimized by screening several liposome formulations of lipid, drug concentration, and 
buffer solution. BRF entrapment efficiency was greater than 90% using this method, 
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and was low using conventional hydration methods. High initial BRF loading using the 
pH gradient method caused aggregation of liposomes. To circumvent aggregation, the 
negatively charged lipid dicetylphosphate was incorporated into liposomes, which 
formed anion layer preventing coalescence. Release of BRF from liposomes was 
sustained for several hours depending on lipid concentration, inner water phase, initial 
drug amounts, and surface properties. Surface modification with chitosan (CS), a 
mucoadhesive cationic polymer, was achieved using electrostatic interactions of 
negatively charged liposomes. The optimal concentration of CS for evasion of liposome 
aggregation was 0.15%. The model NSAID BRF was encapsulated into liposomes 
using the pH gradient method. Formulations were optimized to achieve almost 100% 
drug loading efficiency. 
 
Dr. M. Purushothaman et al49, prepared and evaluated decitabine liposmoes. 
Decitabine Liposomes were prepared by the thin film hydration method using the soya 
lecithin as the phospholipid. Their study mainly explains about the effect of 
concentration of soya lecithin, cholesterol and Tween 80. The prepared liposomes were 
characterized by scanning electron microscopic method respectively. The In-vitro 
release studies were performed and the drug release kinetics was evaluated using linear 
regression method. The objective of the present study was to develop liposome 
containing Decitabine and the prepared liposomes were evaluated for size, shape, drug 
entrapment efficiency, In-vitro drug release and stability. Decetabine loaded liposomes 
formulation had good ability to encapsulate drug and elicted favorable physicochemical 
characteristics. The intestinal absorption and antitumor capacity of Decitabine was 
significantly enhanced by using liposomes. These results suggest that liposomes could 
be a promising perioral carrier for Decitabine. 
 
Deevan Paul And Vothani Sarath Babu50., formulated and evaluated 
liposomal gel containing ketoconazole. Liposomes were prepared by thin film 
hydration technique using ketoconazole, Soya lecithin, Cholesterol were dissolved in 
mixture of chloroform and methanol (9:1) were taken in different levels. 0. The FT-IR 
spectroscopy study was carried out to check out the compatibility between the drug 
Ketoconazole and the excipients used for the preparation. These include average 
particle size and size distribution, shape, encapsulation efficiency, Percentage drug 
content, In-vitro drug release study. The compatibility study of the prepared 
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Ketoconazole Liposomes showed no interaction between drug and excipients. The size 
of liposomal formulations ranged from 3.278- 19.688µm. The entrapment efficiency of 
drug increased when molar ratio of lipid to cholesterol was changed from 1:1% Drug 
content of liposomal formulations obtained shows 94.6 - 99.2% drug content. 
Liposomal dispersion and gel were found to increase the skin permeation and 
deposition compared to control and marketed gel. They concluded that Ketoconazole 
can also be loaded in liposomal carriers which found to be effective, stable and can be 
preceded for further future studies. 
 
Mohamed A. El-Nabarawi et al51., formulated and evaluated dispersed 
paroxetine liposomes in gel. Paroxetine liposomes were prepared by reverse phase 
evaporation technique using soya lecithin, cholesterol and drug in different weight 
ratios. The prepared liposomes were characterized for size, shape, entrapment 
efficiency. The effect of using different weight ratios of soybean lecithin 
phosphatidylcholine: cholesterol  on entrapment efficiency and on drug release was 
studied. Liposomes showed entrapment efficiency percent of 81.22% ± 3.0 8 for 
paroxetine. The optimized paroxetine liposomes formula was F5 (7:7) molar ratio of 
(SLP: CHOL), which after that was incorporated in different based gels at different 
concentrations as Pluronic F127 (PF127-G) (20%, 25%and 30%), Carbopol 934 (C934-
G) (1%, 1.5% and 2%) and Hydroxypropyl methylcellulose E4M (HPMC-G) (2%, 4% 
and 6%) and evaluated through in-vitro release, viscosity, pH and drug content. 
 
M.Yasmin Begum et al52., designed and evaluated  flurbiprofen liposomes. 
Liposomes were prepared by thin film hydration technique using various lipids such as 
soyphosphatidyl choline, dipalmitoyl phosphatidyl choline and distearoyl posphatidyl 
choloine with or without cholesterol. All the prepared formulations were characterized 
for their physico chemical properties such as appearance, vesicle size, vesicle size 
distribution, percentage drug entrapment, stability of the liposomes in terms of their 
drug leakage and drug retention behavior. Stability was studied by storing the liposomal 
formulations under different conditions for the period of 30 days. The optimized 
formulation parameters and process parameters resulted the liposomes in the vesicle 
size range of 4.6±0.6 to 5.6±0.4µm with mean vesicle diameter of 5. The maximum 
percentage drug entrapment was achieved with the formulation which contains the 
distearoyl phosphatidyl choline and cholesterol. In vitro percentage drug release data 
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showed that the release profile follows zero order kinetics and mechanism of drug 
release was diffusion. The flurbiprofen liposomes with good stability and appreciable 
controlled drug release with good retention of the drug even after 24 hours were 
prepared successfully 
 
J S Dua et al53., prepared, optimized, characterized liposomes containing 
serratiopeptidase for oral delivery. The liposome prepared by ethanol injection method 
by using Phosphatidylcholine and cholesterol at 10:10 ratio shown good % Entrapment 
efficiency and In-vitro drug release study. Optimized formulations were subjected to 
stability studies at two different temperatures for up to 45 day. No significant changes 
in drug entrapment efficiency and mean particle size were observed during the course 
of stability study for formulations stored at 4-8ºC but there was a significant decrease 
in drug entrapment efficiency for liposome stored at room temperature after 15, 30 and 
45 days and the mean particle size were increased at room temperature after 15, 30 and 
45 days. 
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LIST OF CHEMICALS 
Table No. 1 
 
S. No INGREDIENTS SOURCE 
1.  Metformin HCL Reachem laboratory chemicals, Chennai 
2.  Cholesterol Reachem laboratory chemicals, Chennai 
3.  Soy lecithin The urban platter food co., Mumbai 
4.  Chloroform RANKEM, Haryana 
5.  Ether RANKEM, Haryana 
6.  Sodium hydroxide Reachem laboratory chemicals, Chennai 
7.  Potassium di hydrogen phosphate Merck specialities pvt. Ltd., Mumbai 
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DRUG PROFILE54, 55, 56 
METFORMIN HCl 
 
DRUG NAME : Metformin hydrochloride 
STRUCTURE   
 
  
MOLECULAR FORMULA : C4H11N5 
MOLECULAR WEIGHT : 129.1636   
CHEMICAL NAME : 1-carbamimidamido-N,N- 
  dimethylmethanimidamide 
CATEGORY    : Anti-hyperglycemic drug 
DOSE   :  500 -2500mg 
DESCRIPTION  : white crystalline powder, odorless, bitter taste 
SOLUBILITY                :   Freely water soluble 
MELTING POINT  :  223-226 °C 
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MECHANISM OF ACTION: 
 Metformin's mechanisms of action differ from other classes of oral anti-
hyperglycemic agents. Metformin decreases blood glucose levels by decreasing hepatic 
glucose production, decreasing intestinal absorption of glucose, and improving insulin 
sensitivity by increasing peripheral glucose uptake and utilization. These effects are 
mediated by the initial activation by metformin of AMP-activated protein kinase 
(AMPK), a liver enzyme that plays an important role in insulin signaling, whole body 
energy balance, and the metabolism of glucose and fats. Activation of AMPK is required 
for metformin's inhibitory effect on the production of glucose by liver cells. Increased 
peripheral utilization of glucose may be due to improved insulin binding to insulin 
receptors. Metformin administration also increases AMPK activity in skeletal muscle. 
AMPK is known to cause GLUT4 deployment to the plasma membrane, resulting in 
insulin-independent glucose uptake.  
PHARMACOKINETICS: 
Absorption:  
 Absorbed over 6 hours, bioavailability is 50 to 60% under fasting conditions. 
Administration with food decreases and delays absorption. Some evidence indicates 
that the level of absorption is not dose-related, suggesting that absorption occurs 
through a saturable process. Limited data from animal and human cell cultures indicate 
that absorption occurs through a passive, non-saturable process, possibly involving a 
paracellular route. Peak action occurs 3 hours after oral administration. 
Distribution: 
 654 L for metformin 850 mg administered as a single dose. The volume of 
distribution following IV administration is 63-276 L, likely due to less binding in the 
GI tract and/or different methods used to determine volume of distribution. 
Metabolism: 
 Metformin is not metabolized. 
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Elimination: 
 Intravenous single-dose studies in normal subjects demonstrate that metformin 
is excreted unchanged in the urine and does not undergo hepatic metabolism (no 
metabolites have been identified in humans) nor biliary excretion. Approximately 90% 
of the drug is eliminated in 24 hours in those with healthy renal function. Renal 
clearance of metformin is approximately 3.5 times that of creatinine clearance, 
indicating the tubular secretion is the primary mode of metformin elimination. 
ADVERSE REACTION: 
 Lactic acidosis is characterized by elevated blood lactate levels (>5mmol/L), 
decreased blood pH, electrolytic disturbance with an increased anion gap and an 
increased lactate / pyruvate ratio. Feeling very weak, tired or unusual muscles pain, 
breathing trouble, unusual stomach discomfort were observed with Metformin. 
Metformin hydrochloride therapy may produce unpleasant or metallic taste, feeling 
cold, dizziness and suddenly developing a slow or irregular heartbeat. Gastrointestinal 
symptoms like diarrhea, nausea, vomiting, abdominal bloating, flatulence and anorexia 
are the most common but very rare (approximately 3%) symptoms. 
INDICATIONS: 
 Metformin is used in patients with type 2 diabetes (non - insulin dependent 
diabetes). Controlling high blood sugar helps prevent kidney damage, blindness, nerve 
problem, loss of limbs and sexual function problem. Proper control of diabetes may 
also lessen the risk of a heart attack or stroke. It also decreases the amount of sugar that 
the liver makes and that the stomach /intestines absorb. 
DOSAGE AND ADMINISTRATION: 
 The usual starting dose of Metformin hydrochloride 500mg tablet is, one tablet 
twice in a day, given with the morning and evening meals. Metformin hydrochloride 
can be administered up to 2000mg per day (twice a day). The maximum recommended 
daily dose for Metformin hydrochloride in adult is 2000mg.  
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CONTRAINDICATION: 
 Metformin is contraindicated in people with any condition that could increase 
the risk of lactic acidosis, including kidney disorders, lung disease and liver disease. 
Metformin is recommended to be temporarily discontinued before any radiographic 
study involving iodinated contrast agents (such as contrast – enhanced CT scan or 
angiogram), as the contrast dye may temporarily impair kidney function,  indirectly 
leading to lactic acidosis by causing retention of Metformin in the body. 
MARKETED PRODUCTS: 
 Metlong – D, Glumet, Sumet, Daomet, Diamet, Gluconorm, GluforminXL, K-
met, Glyciphage, Melmet, Obimet, Zoform. 
OTHER DOSAGE FORMS: 
 Pio – MF bilayered tablets, Glycheck – MF conventional tablets, Riomet oral 
solution. 
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SOYA LECITHIN57, 58, 59, 60 
NON – PROPRIETARY NAME : Lecithin 
SYNONYMS : Mixed soybean phosphatides, ovolecithin, mixed soybean phosphatides, ovolecithin, 
soybean lecithin, soybean phospholipids, 
vegetables lecithin. 
EMPRICAL FORMULA : C42H80NO8P 
MOLECULAR WEIGHT : 758.06g/mol 
STRUCTURAL FORMULA :  
MELTING POINT : -5˚C (23˚F) 
FUNCTIONAL CATEGORY : Emollient; emulsifying agent; solubilizing
agent. 
DESCRIPTIONS : Solid, White or faintly yellow pearly granules 
or crystals 
SOLUBILITY : Insoluble in water, soluble in chloroform, 
ethanol and ether. 
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STABILITY : Stable, but light, heat, moisture and air-sensitive. 
Incompatible with strong oxidizing agents. 
APPLICATIONS : Hypolipidemic ingredients ,  nutrition 
supplements, humectant and emulsifiers 
STORAGE : Do not store in direct sunlight. Store in a tightly 
closed container. Store in a cool, dry, well-
ventilated area away from incompatible 
substances. Storage temperatures should not 
exceed 75ºF. 
STABILITY : Stable under ordinary conditions of use and 
storage. 
INCOMPATIBILITIES : Excessive heat and flames, Avoid strong 
oxidizers, incompatible with esterases owing to 
hydrolysis. 
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CHOLESTEROL61, 62 
NON- PROPRIETARY NAME : BP: Cholesterol, 
 JP: Cholesterol,  
PhEur: Cholesterol,  
USP-NF: Cholesterol 
SYNONYMS : Cholesterin, cholesterolum. 
EMPRICAL FORMULA :  C27H46O 
MOLECULAR WEIGHT : 386.664 g/mol 
STRUCTURAL FORMULA :
MELTING POINT : 148.5 °C 
FUNCTIONAL CATEGORY : Emulsifying agent, 
DESCRIPTIONS : Solid, White or faintly yellow pearly granules or 
crystals and white crystalline powder. 
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SOLUBILITY : Lower solubility in water, soluble in ethanol, 
methanol, hexane, acetone, ether, chloroform and 
benzene. 
APPLICATIONS : Cholesterol is used in liposomes to encapsulate and 
deliver chemotherapeutic drugs to diseased tissues, 
Cholesterol-C14 is used clinically as an organ imaging 
agent. Organs visualized by the technique include 
ovaries, adrenals, and spleen. 
STORAGE : Stored in well close container, protect from direct 
sunlight and away from oxidizing agent. 
STABILITY :  Stable under ordinary condition 
INCOMPATIBILITIES : Incompatible with strong oxidizing agents 
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CHLOROFORM63, 64 
SYNONYMS : Trichloromethane, Formyl trichloride, 
Trichloroform, Methenyl chloride, 
Methenyl trichloride. 
EMPRICAL FORMULA : CHCl3 
MOLECULAR WEIGHT : 119.369 g/mol 
STRUCTURAL FORMULA :
MELTING POINT : -63.2 °C 
FUNCTIONAL CATEGORY : Inhaled anesthetic and used as a solvent 
DESCRIPTIONS : Clear colorless liquid with a characteristic 
odor 
SOLUBILITY : Slightly soluble in water and soluble in 
carbon disulfide, 
APPLICATIONS : Chloroform was used in the past as an 
extraction solvent for fats, oils, greases, and 
other products; as a dry cleaning spot 
remover; in fire extinguishers; as a fumigant 
and as an anesthetic. 
STORAGE : It is to be stored in a cool, dry, well-
ventilated place, out of direct light. 
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STABILITY : Decomposes at ordinary temp in sunlight in 
the absence of air, and in the dark in the 
presence of air. 
INCOMPATIBILITIES : It is incompatible with dinitrogen tetraoxide, 
fluorine, sodium metal and alcohols, 
nitromethane, and triisopropylphosphine. 
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ETHER65, 66, 67 
SYNONYMS : Diethyl ether, Ethyl ether, Ethoxyethane, Diethyl 
oxide, Ethyl oxide 
EMPRICAL FORMULA : C4H10O 
MOLECULAR WEIGHT : 74.123 g/mol 
STRUCTURAL FORMULA : 
MELTING POINT : -116°C 
FUNCTIONAL CATEGORY : Fuels and fuel additives, Functional fluids (closed 
systems), Propellants and blowing agents 
DESCRIPTIONS : Clear colorless liquid with an anesthetic odor 
SOLUBILITY : Soluble in acetone, naphtha, benzene and oils, very 
soluble in ethanol 
 EXCIPIENTS PROFILE 
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APPLICATIONS : Anesthetic, It is a great solvent for fats, waxes, oils, 
perfumes, alkaloids, and gums. 
STORAGE : Ethers should be stored in tightly closed containers 
within properly labelled fire resistant metal 
cabinets, or bins, and on drip trays. They must be 
stored separate from oxidizers. 
STABILITY : Ether is stable under normal ambient and 
anticipated storage and handling conditions of 
temperature and pressure. 
INCOMPATIBILITIES : It is incompatible with acids, bases, oxidizers, and 
poisons. 
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METHANOL68, 69, 70 
SYNONYMS : Methyl alcohol, wood alcohol, carbinol, 
wood spirit, wood naphtha, methylol, 
methyl hydroxide, pyroxylic spirit, 
colonial spirit, columbian spirit, 
monohydroxymethane, methylalkohol 
EMPRICAL FORMULA : CH3OH 
MOLECULAR WEIGHT : 32.042 g/mol 
STRUCTURAL FORMULA : 
MELTING POINT : -97.6 °C 
FUNCTIONAL CATEGORY : Industrial solvent 
DESCRIPTIONS : Colourless liquid with characteristic 
odour. 
SOLUBILITY : Miscible with ethanol, ether, benzene, 
most organic solvents and ketones, 
Soluble in acetone, chloroform 
APPLICATIONS : Methanol is primarily used as an 
industrial solvent for inks, resins, 
adhesives, and dyes. It is also used as a 
solvent in the manufacture of 
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cholesterol, streptomycin, vitamins, 
hormones, and other pharmaceuticals. 
STORAGE : Store in a segregated and approved area. 
Keep container in a cool, well-ventilated 
area. Keep container tightly closed and 
sealed until ready for use. Avoid all 
possible sources of ignition (spark or 
flame). 
STABILITY : Stored in well close container, protect 
from direct sunlight and away from 
oxidizing agent. 
INCOMPATIBILITIES : It is incompatible with acids, bases, 
oxidizers and poisons. 
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LIST OF EQUIPMENTS 
Table No. 2  
S.No EQUIPMENT NAME EQUIPMENT MANUFACTURER 
1. Magnetic stirrer Remi equipment Pvt.Ltd 
2. Digital Balance ORSON 
3. Optical microscopy Olympus opto systems India Pvt. Ltd, Noida
4. UV spectrophotometer UV – 1800 SHIMADZU corporation, Japan 
5. Cooling centrifugator Remi elektrotecnik limited, vasai, India. 
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METHODOLOGY 
CONSTRUCTION OF STANDARD CURVE OF METORMIN HCL 
Preparation of 0.2M Potassium di hydrogen phosphate: 
 Accurately weighed 27.218 gm of potassium di hydrogen phosphate was 
dissolved in distilled water and make up to 1000 ml with distilled water. 
Preparation of 0.2M Sodium hydroxide solution: 
 Accurately weighed 8.0 gm of sodium hydroxide was dissolved in distilled 
water and make up to 1000 ml with distilled water. 
Preparation of ph 6.8 phosphate buffer 
 500 ml of 0.2 M potassium di hydrogen phosphate and 224 ml of 0.2 M sodium 
hydroxide solution was mixed together and made up to 2000 ml with distilled water. 
Then it was adjusted to pH 6.871. 
Preparation of standard curve of Metformin HCl using pH 6.8 phosphate buffer72: 
 Accurately weighed 100 mg metformin HCl was dissolved in water and the 
volume was make up to 100 ml using distilled water in a volumetric flask to obtain a 
solution of 1000 µg/ml. From the above solution 10 ml was pipetted out into a 100 ml 
volumetric flask and made up to 100 ml using phosphate buffer pH 6.8 to get a stock 
solution of 100 µg/ml. From this stock solution, aliquots of 0.2ml, 0.4ml, 0.6ml, 0.8ml, 
1.0ml, 1.2ml, 1.4ml, 1.6ml, 1.8 ml and 2.0ml were pipetted out into a series of 10 ml 
volumetric flask and made up to mark with phosphate buffer pH 6.8 to get a 
concentration in the range of 2 to 20 µg/ml. The absorbance of the resulting solution 
was then measured at 233 nm using UV Double beam spectrophotometer against 
phosphate buffer pH 6.8 as blank. The standard curve was obtained by plotting 
concentration (µg/ml) values in X- axis and absorbance values in Y – axis. 
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STANDARD CURVE DATA OF METFORMIN HCL USING PHOSPHATE BUFFER pH 6.8 
Table No. 3 Standard curve data of Metformin HCl using phosphate buffer                 
p H 6.8 
 
S. No. Concentration (µg/ml) Absorbance at 233 nm 
1.  2 0.189 
2.  4 0.370 
3.  6 0.524 
4.  8 0.699 
5.  10 0.858 
6.  12 1.055 
7.  14 1.244 
8.  16 1.394 
9.  18 1.568 
10.  20 1.716 
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Figure No. 4 Standard curve of Metformin HCl 
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PREFORMULATION STUDIES 
 Preformulation testing is an investigation of physical and chemical 
properties of a drug substance alone and when combined with excipients. It is the first 
step in the rational development of dosage form. The objective of preformulation testing 
is to generate information useful to the formulation in developing stable and stable and 
bioavailable dosage forms. The use of preformulation parameters maximize the chances 
in formulating an acceptable, safe, efficacious and stable product73. 
A) Solubility 
 Solubility of Metformin Hcl in water, methanol, phosphate buffer pH 6.8 
was determined at room temperature with the help of magnetic stirrer. 
Approximate solubility of drug was indicated from the following limits: 
Very soluble: 1 part of the substance is soluble less than 1 part of the solvent. 
Freely soluble: 1 part of the substance is soluble in 1 to 10 parts of the solvent. 
Soluble: 1 part of the substance is soluble in 10 to 30 parts of the solvent. 
Sparingly soluble: 1 part of the substance is soluble in 30 to 100 parts of the solvent. 
Slightly soluble: 1 part of the substance is soluble in 100 to 1,000 parts of the solvent. 
Very slightly soluble: 1 part of the substance is soluble in 1000 to 10,000 parts of the 
solvent. 
Practically insoluble or insoluble: More than 10,000 parts of the solvent is required 
to dissolve 1 part of substance74. 
 
B) Melting Point 
Melting point determination was done by using melting point apparatus. 
Small amount of pure drug of Metformin HCl was taken in a capillary tube and it was 
kept in the melting point apparatus and the melting point was noted75. 
Drug – excipients interaction studies: 
 FT-IR spectra were taken for the dried samples using FT-IR 8400S (Shimadzu, 
Japan) to determine the possible interactions between the drug and polymers. The plain 
drug, individual lecithin and cholesterol, combination of drug with cholesterol and 
lecithin in three different ratio (1:1, 1:2 and 1:3) were taken and mixed with KBr. 
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The samples were compressed to form a pellet using a hydraulic press.  The 
prepared pellets were transformed into disk. The disk was applied to the centre of the 
sample holding device and scanned from 4,500 to 400 cm-1 using FT-IR 
spectrophotometer76.  
Formulation of liposomes loaded with Metformin hydrochloride: 
 The formulation of liposomes loaded with Metformin HCl was prepared by two 
different techniques namely, physical dispersion method and ether injection method. In 
both the techniques ratio of cholesterol was kept as same and the lecithin concentration 
was increased as 1:1, 1:2 and 1:3.  
Physical dispersion method: 
Liposomes were prepared by physical dispersion method using different ratio 
of soya lecithin and cholesterol was kept as constant. In this method the soya lecithin 
and cholesterol were dissolved in chloroform. Then it was spread over flat bottom 
conical flask and allowed to evaporate at room temperature for overnight without 
disturbing the solution for a formation of lipid film.  The drug was dissolved in 
phosphate buffer pH 6.8. It act as an aqueous medium. Then the aqueous medium was 
added to the lipid film for hydration. For this the flask was inclined to one side and 
aqueous medium was introduced down the side of flask and flask was slowly returned 
to upright orientation. Then the conical flask was kept on water bath and the 
temperature was maintained at 37± 2ºC for 2 hours for the completion of hydration. 
The conical flask was gently shaken until the lipid layer was removed from wall of 
conical flask and formation a liposomes suspension. Then the formed liposomes 
suspension was stored at 4ºC for one day for the maturation of liposomes. The prepared 
liposome suspension was centrifuged at 15,000 rpm for 20 mins. Then the precipitate 
was collected and diluted with distilled water for further studies35. Different batches of 
liposomes were prepared as per the general method described above and composition 
for the preparation of liposomes is given in Table 5. 
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Ether injection method: 
 Liposomes were prepared by ether injection method using different ratio of 
soya lecithin and cholesterol was kept as constant. In this method the cholesterol and 
soya lecithin were dissolved in ether and methanol. The drug was dissolved in 
phosphate buffer pH 6.8. It act as an aqueous medium. The aqueous medium was heated 
to 60°C. The method involves injecting drop by drop of ether-lipid solutions into the 
above warmed aqueous medium. The ether vaporizes upon contacting the aqueous 
phase, and the dispersed lipid forms primarily unilamellar liposomes. Then the product 
was collected and it was stored at 4°C for maturation of liposome. Then prepared 
liposomal suspension was centrifuged at 15,000 rpm for 20 mins. The precipitate was 
diluted with distilled water for evaluation studies77. Different batches of liposomes were 
prepared as per the general method described above and composition for the preparation 
of liposomes is given in Table No. 4. 
Table No. 4 Formulation of Metformin HCl liposomes 
 
 
 
S. No. Ingredients 
Physical dispersion method Ether injection method 
F 1 F 2 F 3 F 4 F 5 F 6 
1.       
 Cholesterol 100 mg 100 mg 100 mg 100 mg 
100 
mg 100 mg 
2.       
 Lecithin 100 mg 200 mg 300 mg 100 mg 
200 
mg 300 mg 
3.       
 Metformin HCl 10 gm 10 gm 10 gm 10 gm 10 gm 10 gm 
4.       
 Ether - - - 7 ml 7 ml 7 ml 
5.       
 Methanol - - - 3 ml 3 ml 3 ml 
6 Chloroform  5 ml 5 ml 5 ml - - - 
7. Phosphate buffer pH 6.8 50 ml 50 ml 50 ml 50 ml 50 ml 50 ml 
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EVALUATION OF LIPOSOMES: 
1. Determination of percentage drug entrapment efficiency: 
 Drug entrapment efficiency was calculated by using centrifugation method. 10 
ml of liposome suspension was taken and centrifuged at 15,000 rpm for 20 mins. The 
supernatant liquid was collected and suitably diluted. Then the absorbance was taken at 
233 nm with the help of UV double beam spectrophotometer using pH 6.8 as a blank. 
The drug entrapment efficiency was calculated from the following formula78. 
 
Total entrapment efficiency =  ୅୫୭୳୬୲ ୭୤  ୢ୰୳୥ ୧୬ ୱ୳୮ୣ୰୬ୟ୲ୟ୬୲ ୪୧୯୳୧ୢ୅୫୭୳୬୲ ୭୤ ୢ୰୳୥   × 100 
2. Morphology analysis: 
The prepared Metformin HCl liposomes for all the formulations were viewed 
under for observing the vesicle formation and discreteness of dispersed vesicles. A slide 
was prepared by placing a drop of liposome dispersion on a glass slide and cover slip 
was placed over it and this slide was viewed under optical microscope at 40X 
magnification. Photographs were taken to prepared slides using digital camera33. 
 
3. In vitro drug release study: 
Apparatus  : USP TYPE II (Paddle) 
RPM  : 50 
Temperature  : 37ºC ± 0.5ºC 
Time : 30 min. interval Upto 8 hrs  
The in vitro release for all the formulated Metformin HCl liposomes were carried out 
for 8 hours in phosphate buffer p H 6.8. The studies were carried in USP dissolution 
apparatus II (Paddle) at 37ºC ± 0.5ºC and 50 rpm speed. 900 ml of phosphate buffer p 
H 6.8 was used as a dissolution medium. Equivalent to 100 mg of Metformin HCl 
liposome was taken in a dissolution jar contains dissolution medium and the paddle was 
rotated at 50 rpm. 1 ml of samples were withdrawn at every 30 min. upto 480 mins and 
make upto 10 ml with pH 6.8 and analyzed for Metformin HCl content at 233 nm with 
pH 6.8 as blank using double beam UV double beam spectrophotometer79. 
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4. Particle size determination: 
The particle size determination is done by using Malven particle size analyzer. 
Groups of particles are dispersed in a liquid medium and measured as they are circulated 
between the flow cell, which is placed in the measurement unit, and a dispersion bath 
in the sampler. The dispersion bath incorporates a stirrer and an ultrasonic sonicator. A 
pump delivers the dispersed suspension to the flow cell. The pump is specially designed 
to ensure both liquid medium and the particles are circulated. It can be controlled from 
a PC. Organic solvents can be used as dispersion media80. 
5. Stability studies: 
The behavior of the liposome to retain the drug was studied by storing the 
liposome at two different temperature conditions, i.e., 4ºC (refrigerator RF), 25°C±2ºC 
for a period of 1 month. The liposomal preparations were kept in sealed vials. At 30th 
day the samples were analyzed for the drug content following the same method 
described in % drug encapsulation efficiency and in vitro drug release. And also the 
liposomes were studied for their morphology81. 
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RESULTS AND DISCUSSION 
The research study was aimed to formulate Metformin HCl liposomes to sustain 
the action of drug for over the period of 8 hours. The liposomes were prepared by 
physical dispersion method and ether injection method. Soya lecithin and cholesterol 
were used for encapsulating the drug and also to release the drug in sustained manner. 
Chloroform, ether and methanol were used as a solvent. Phosphate buffer pH 6.8 was 
used as a hydration medium for loading the drug. 
Preformulation studies such like solubility analysis, melting point and FT – IR 
studies were carryout before the formulations. After formulation, the liposomes were 
evaluated for various parameters like percentage drug entrapment efficiency, 
microscopic analysis, particle size analysis, in vitro drug release studies and stability 
study. 
PREFORMULATION STUDIES 
A) Solubility 
The drug should be dissolve in solvents and also dissolution medium so the 
solubility analysis for the drug was important. The solubility of raw drug was 
determined by dissolving in distilled water, methanol and phosphate buffer pH 6.8. The 
drug was found to be freely soluble in water, soluble in methanol and phosphate buffer 
p H 6.8.  
B) Melting point 
The melting point was confirmed the Metformin HCl present in raw material of 
drug. It was found to be 224ºC within the specification range. So it confirmed 
Metformin HCl present in raw material of drug. 
 
C) DRUG – EXCIPIENTS INTERACTION STUDIES: 
The FT – IR studies of pure Metformin HCl, cholesterol, soya lecithin and 
Metformin HCl+ cholesterol + soya lecithin were conduct to study the interaction 
between the drug and excipients. 
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IR spectral analysis showed that the fundamental peaks and patterns of the 
spectra were similar both in pure drug and combination containing drug and highest 
proportion of excipients. This indicated that there was no chemical interaction between 
Metformin HCl and the other excipients used in the formulations. The spectral datas 
are presented in Table No. 5 - 8 and spectral peaks were presented graphically in Figure 
No. 5 – 9. 
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FT – IR SPECTRUM OF PURE METFORMIN HCL 
 
Figure No. 5 FT – IR Spectrum of pure Metformin HCl 
Table No. 5 FT – IR Spectrum of pure Metformin HCl 
Wave length 
(cm-1) 
Functional group 
3372  N-H stretching 
1582 Amino N-H bending 
1466  CH3 bending alkanes 
1057  C-N Stretching 
957  Alkene C-H bending 
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FT – IR SPECTRUM OF CHOLESTEROL 
 
Figure No. 6 
 
Table No. 6 FT – IR Spectrum of cholesterol 
Wave length(cm-1) Functional group 
3421 N-H stretching 
1466  CH3 bending alkanes 
1057  C-N Stretching 
955  Alkene C-H bending 
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FT – IR SPECTRUM OF SOYA LECITHIN 
 
Figure No. 7 
Table No. 7 FT – IR Spectrum of soya lecithin 
Wave length (cm-1) Functional group 
3379 N-H stretching 
1620 Amino N-H bending 
1464 CH3 bending alkanes 
1104 C-N Stretching 
864 Alkene C-H bending 
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FT – IR SPECTRUM OF COMBINATION OF METFORMIN HCl, 
CHOLESTEROL AND SOYA LECITHIN 
 
 Figure No. 8 
Table No. 7 FT – IR Spectrum of combination of Metformin HCl + cholesterol + 
soya lecithin 
Wave length (cm-1) Functional group 
3372 N-H stretching 
1582 Amino N-H bending 
1466 CH3 bending alkanes 
1057 C-N Stretching 
957 Alkene C-H bending 
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Table No. 8 
FT – IR Spectrum of pure Metformin HCl, cholesterol, soya lecithin and 
combination of Metformin HCl + cholesterol + soya lecithin 
Functional 
group 
N-H 
stretching 
(cm-1) 
Amino N-H 
bending 
(cm-1) 
CH3 
bending 
alkanes 
(cm-1) 
C-N 
Stretching 
(cm-1) 
Alkene C-H 
bending 
(cm-1) 
Drug 3372  1582  1466 1057 957 
Cholesterol 3421  - 1466  1057 955 
Soya 
lecithin 3379  1620  1464  1104 864 
Combination 
of drug + 
cholesterol + 
soya lecithin 
3372 1582 1466 1057  957 
 
EVALUATON OF METORMIN HCL LIPOSOMES 
Percentage drug entrapment efficiency 
The percentage drug entrapment efficiency of liposomes were prepared by 
physical dispersion method and ether injection method. The formulations was 
formulated by varying the cholesterol – soya lecithin ratio. It was found to be that 
percentage drug entrapment efficiency of formulations F 1, F 2 and F 3 were 86.60 %, 
79.90 % and 73.10 % respectively and formulations F 4, F 5 and F 6 were 30.47%, 
39.58% and 39.69% respectively. The results may adjudge physical dispersion method 
have better drug entrapment efficiency than ether injection method. 
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Morphology analysis 
The morphology characters of liposomes were analyzed by optical microscopy 
(Olympus Opto System, India) and the images were taken using digital camera. The 
formulation F 1, F 2, F 3,    F4, F 5 and F 6 microscopic images were showed in Figure 
No. 9 -14. 
Prepared liposomes F 1 to F 6 shows well identified morphology characters. 
 
Figure No. 9 Microscopic 
image (45 X) of  F 1 
formulation 
Figure No. 10 Microscopic 
image (45 X) of  F 2 
formulation 
Figure No. 11 
Microscopic image (45x) 
of  F 3 formulation 
Figure No. 12 Microscopic 
image (45x) of  F 4 
formulation 
Figure No. 13 Microscopic 
image (45x) of  F 5 
formulation 
Figure No. 14 
Microscopic image (45x) 
of  F 6 formulation 
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Particle size analysis 
The particle size analysis was carried out by particle size analyzer for all the 
prepared liposome formulations. The particle size for all the formulated liposomes were 
found be in the range of 30.617 µm to 0.031µm as shown in Table No. 7 and graphically 
showed in Figure No. 15 to 20.  The particle size data showed that when the 
concentration of soya lecithin was increased the particle size was decreased for all the 
formulations of Metformin HCl liposomes in prepared by both methods. The particle 
size of Metformin HCl liposomes of F 3 and F 6 were found to be lower when compared 
with other formulations this may be due to higher concentration of soya lecithin.  
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 Figure No. 15 Particle size range of F 1 formulation 
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Figure No. 16 Particle size range of F 2 formulation 
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Figure No. 17 Particle size range of F 3 formulation 
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Figure No. 18   Particle size range of F 4 formulation 
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 Figure No. 19   Particle size range of F 5 formulation 
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Figure No. 20   Particle size range of F 6 formulation 
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Table No. 9 Particle size of all the formulations of Metformin HCl liposomes 
S. No. Formulations Particle size range 
1.  F 1 30.617 – 1.563 µm 
2.  F 2 19.023 – 1.563 µm 
3.  F 3 0.071 -0.031µm 
4.  F 4 24.133 – 1.563 µm 
5.  F 5 0.081 – 0.031 µm 
6.  F 6 0.071 -0.031µm 
  
 
In vitro drug release studies 
 In vitro release studies were performed to evaluate the release of drug from the 
prepared Metformin HCl liposomes. The result of the in vitro release studies of all 
formulation were presented in Table No. 10. 
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Table No. 10 Cumulative percentage drug released of Metformin HCl from 
liposomes 
 All the values expressed as mean± standard deviation, n = 3 
The Metformin HCl liposomes were prepared by physical dispersion method 
and ether injection method using different ratio of cholesterol and soya lecithin. The 
cumulative percentage drug release was compared with different formulations. 
The cumulative percentage drug release of formulations F 1, F 2 and F 3 were 
found to be 103.03±2.47, 91.92±2.72 and 82.12±2.51 respectively in 8 hours.  The 
 
S. 
No 
Time 
(Mins
) 
F – 1 F - 2 F - 3 F – 4 F - 5 F – 6 
1. 30 9.31±0.94 8.92±0.52 8.16±0.63 8.64±0.48 7.53±0.58 2.74±0.33 
2. 60 15.76±0.59 12.19±0.61 11.24±0.80 16.63±0.67 13.73±0.37 5.34±0.94 
3. 90 24.47±1.13 18.60±1.72 15.84±1.26 24.16±1.28 19.19±0.94 9.79±1.27 
4. 120 32.70±2.54 25.22±1.47 20.78±2.42 31.48±1.88 26.48±0.71 15.75±0.57
5. 150 40.48±2.20 30.44±3.18 26.11±2.36 39.54±2.12 33.31±0.48 21.56±0.95
6. 180 45.49±1.85 36.58±3.54 30.60±2.44 47.31±2.30 38.18±0.43 26.58±0.42
7. 210 50.25±1.90 41.20±3.80 35.19±2.47 55.12±2.44 42.81±1.27 30.09±0.97
8. 240 57.43±1.72 47.65±3.87 38.49±2.61 62.44±2.32 47.44±2.58 33.31±1.51
9. 270 65.91±1.45 53.68±3.55 43.26±2.61 69.45±2.12 52.66±1.57 37.28±1.57
10. 300 74.00±3.11 58.45±3.00 46.98±2.38 76.56±1.47 57.29±1.36 42.40±2.03
11. 330 81.77±2.78 63.71±3.21 50.45±2.37 83.81±1.64 61.95±1.91 46.19±2.00
12. 360 88.04±2.81 69.84±3.56 55.85±2.37 91.06±1.57 66.51±1.36 51.41±1.88
13. 390 92.43±2.07 75.66±3.03 62.30±2.37 97.61±1.86 73.10±0.10 57.40±1.75
14. 420 95.83±2.11 80.70±2.63 69.23±2.51 100.58±1.58 79.13±1.61 64.06±1.55
15. 450 99.76±2.02 86.52±3.09 75.36±2.51 - 82.08±1.66 71.34±1.40
16. 480 103.03±2.47 91.92±2.72 82.12±2.51 - 85.06±1.73 79.05±1.03
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formulation F 1 show faster release than formulations F 2 and F 3 due to the lower 
concentration of soya lecithin. 
The cumulative percentage drug release of formulations F 4 was found to be 
100.58 ± 1.58 at the end of 7 hours. And the cumulative percentage drug release of 
formulations F 5 and F 6 were found to 85.06±1.73 and 81.39±1.12 respectively in 8 
hours.  The formulation F 4 show faster release than formulations F 5 and F 6. While 
the concentration of soya lecithin was increase it decrease the release of drug. 
The prepared liposomes F 1 to F 6 showed sustained release of drug. When 
increased ratio of soya lecithin also sustain the release of drug was increased in both 
method of preparations.  
The Figure No. 21 and 22 shows the formulation F 1, F 2 and F 3 and F 4, F 5 
and F 6 respectively in 8 hours. 
 
Figure No. 21 Comparative cumulative percentage drug release of Metformin 
HCl liposome formulations of F 1, F 2 and F 3 
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Figure No. 22 Comparative cumulative percentage drug release of Metformin 
HCl liposome formulations of F 4, F 5 and F 6 
 
STABILITY STUDIES 
 All the formulations of Metformin HCl liposomes were relatively stable at 4ºC 
storage condition. The drug leakage percent amounts of original entrapped in liposomes 
were very small and the amount retained in vesicle had no significant difference after 
one month as compared to the amount immediately after preparation. But at the storage 
condition of 25°C±2°C, all the formulations of Metformin HCl liposomes were 
unstable. In addition, the result of drug entrapment studies showed higher leakage at 
higher temperature. This may be due the higher fluidity of lipid bilayer at higher 
temperature, resulting into higher drug leakage. 
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Table No. 11 Stability study of percentage drug entrapment of liposomes 
Metformin HCl liposomes compared with percentage drug entrapment of 
immediately after preparation. 
S. 
No. 
Formulations 
code 
Immediately after 
preparation (%) 
After one month 
At 4°C At 25°C±2ºC 
1. F 1 86.60 85.92% 76.87% 
2. F 2 79.90 % 77.99% 70.98% 
3. F 3 73.10 % 72.08% 66.89% 
4. F 4 30.47% 29.35% 24.89% 
5. F 5 39.58% 38.44% 35.39% 
6. F 6 39.69% 38.36% 36.69% 
 
The morphological characters of Metformin HCl liposomes for F 1 – F 4 didn’t 
show any characteristic changes after it was stored at 4ºC and 25ºC±2ºC for a period of 
one month. F 5 and F 6 formulations were showed slightly reduced in the size after it 
was stored at 25ºC±2ºC for a period of one month but there was no changes for the 
same formulation when it was stored at 4ºC. Microscopic images of all the formulations 
(F 1 – F 6) of Metformin HCl liposomes were compared with before and after stability 
stability studies were shown in Figure No. 23 – 40. 
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Morphology characters of liposomes – Before and after stability 
study 
Figure No. 23  F 1, Immediately 
after preparation (45x) 
Figure No. 24  F 1, After stability 
study at 4ºC (45x) 
Figure No. 25  F 1, After stability 
study at 25ºC±2ºC (45x) 
Figure No. 26  F 2 Immediately 
after preparation (45x) 
Figure No. 27  F 2, After stability 
study at 4ºC (45x) 
Figure No.28  F 2, After stability 
study at 25ºC±2ºC (45x) 
Figure No. 29  F 3, Immediately 
after preparation (45x) 
Figure No. 30 F 3, After stability 
study at 4ºC (45x) 
Figure No. 31  F 3, After stability 
study at 25ºC±2ºC (45x) 
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Figure No. 32  F 4, Immediately 
after preparation (45x) 
Figure No. 33  F 4, After stability 
study at 4ºC (45x) 
Figure No. 34  F 4, After stability 
study at 25ºC±2ºC (45x) 
Figure No. 35  F 5, Immediately 
after preparation (45x) 
Figure No. 36  F 5, After stability 
study at 4ºC (45x) 
Figure No. 37 F 5, After stability 
study at 25ºC±2ºC (45x) 
Figure No. 38 F 6, Immediately 
after preparation (45x) 
Figure No. 39 F 6, After stability 
study at 4ºC (45x) 
Figure No. 40 F 6, After stability 
study at 25ºC±2ºC (45x) 
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After one month, Metformin HCl liposomes formulations F 1 to F 6 were 
showed difference in in vitro drug release profile. Dissolution rate was decreased in all 
Metformin HCl liposomes formulations at both storage conditions like 4°C and 
25ºC±2ºC. The results of in vitro drug release of all the formulations at both storage 
conditions were compared with before and after stability studies and the results were 
shown in Table No. 10 and Figure No. 40. 
Table No. 12 In vitro drug release data of all the Metformin HCl liposome formulations 
after stability study, compared with before stability 
S. No. Formulation code Immediately after preparation
After stability study 
At 4°C At 25ºC±2ºC 
1.  F 1 103.03±2.47 91.81 73.38 
2.  F 2 91.92±2.72 86.77 68.26 
3.  F 3 82.12±2.51 77.91 64.37 
4.  F 4 100.58±1.12 91.74 87.41 
5.  F 5 85.06±1.73 78.81 61.81 
6.  F 6 79.05±1.03 73.98 63.32 
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Figure No. 41 In vitro drug release data of all the Metformin HCl liposome formulations 
after stability study, compared with before stability 
 
 
 At storage condition 4°C showed better stability than another condition. This 
may due to their elevated temperature reduce the stability. But in both storage condition 
higher proportion of soya lecithin contains formulations like F 3 and F 6 showed better 
stability than other their formulations. 
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SUMMARY AND CONCLUSION 
 
This study concluded that Metformin HCl was successfully prepared as a 
liposomal drug delivery system by using two different techniques such as physical 
dispersion method and ether injection method. In this liposomes preparations, 
cholesterol ratio was constant and soya lecithin concentrations were gradually increased 
(like 1:1, 1:2 and 1:3). The liposomes prepared by physical dispersion method showed 
better percentage drug entrapment when compared with ether injection method.  The 
morphological characters of prepared liposomes were determined with the help of 
optical microscope. The particle size was analyzed by Malven particle size analyzer. 
The results of the particle size showed, when the concentration of soya lecithin was 
increased the size of the particle was reduced. The in vitro release showed that as the 
concentration of soya lecithin was increased the release rate of drug was retarded. 
Among the two methods ether injection method showed prolonged action when 
compared to physical dispersion method. The stability studies for all the formulations 
were performed by keeping the formulations at two different temperatures 4ºC±2ºC and 
25ºC±2ºC for a period of 30 days. After the stability period the formulations were tested 
for morphological analysis, percentage drug entrapment and in vitro drug release and 
compared with before stability study. There was no change in morphological characters 
at 4ºC±2ºC, but there was a slight reduced in particles size at 25ºC±2ºC. The percentage 
drug entrapment was reduced in all the formulations at both the conditions. The in vitro 
drug release was reduced for all the formulations. Liposomes prepared by physical 
dispersion method showed better stability compared with ether injection method. 
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